🏷

Classifications

Harrison's Part

🔗

Mappings

ICD-10-CM

ICD10CM:O14.2 HELLP syndrome

MONDO:0008585 carries ICD10CM:O14.2 as a cross-reference, and the French CONCEPTION cohort study operationalizes HELLP syndrome case ascertainment using exactly this code.

📘

Definitions

2

Tennessee Classification System for HELLP syndrome

Sibai's strict laboratory criteria for "true" or "complete" HELLP syndrome. All three components must be present; cases meeting only one or two are termed partial or incomplete HELLP (and, where hemolysis is absent, ELLP).

DIAGNOSTIC_CRITERIA Diagnostic case definition for complete HELLP syndrome; the more widely used of the two systems for establishing whether a case is HELLP at all.

Tennessee complete-HELLP criteria

All three laboratory criteria required for complete HELLP syndrome.

Inclusion criteria

Hemolysis Intravascular hemolysis, evidenced by an abnormal peripheral blood smear, raised serum bilirubin (>= 20.5 micromol/L or >= 1.2 mg/100 mL), and LDH > 600 U/L.
Elevated liver enzymes AST >= 70 IU/L.
Low platelet count Platelets <= 100 x 10^9/L.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

Source for all three thresholds transcribed into this criteria set.

Show evidence (2 references)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

States the three Tennessee thresholds transcribed into this criteria set.

PMID:19245695 SUPPORT Human Clinical

"Intravascular haemolysis is diagnosed by abnormal peripheral blood smear, increased serum bilirubin"

Specifies how the hemolysis component of the Tennessee criteria is established.

Notes: The published Tennessee platelet criterion is written as "< 100" in the review's prose and "<= 100" in its Table 1; the criteria set records the table form. This is a real inconsistency in the source, not a transcription error.

Mississippi Triple-Class HELLP System

Martin's severity grading, which stratifies HELLP by the platelet nadir reached at any point in the illness rather than by presenting values. Class 1 and 2 additionally require LDH > 600 U/L and AST or ALT >= 70 IU/L; class 3 relaxes the transaminase threshold to >= 40 IU/L and is regarded as a clinically significant transition phase capable of progressing. Unlike the Tennessee system this is a severity axis, not an inclusion test - the two answer different questions and should not be conflated.

DIAGNOSTIC_CRITERIA Severity classification of established HELLP syndrome, used to guide the intensity of surveillance and intervention.

Mississippi class 1 (severe)

Platelet nadir <= 50 x 10^9/L, with AST or ALT >= 70 IU/L and LDH >= 600 IU/L.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts."

Source for grading Mississippi class on the platelet nadir.

Mississippi class 2 (moderate)

Platelet nadir > 50 and <= 100 x 10^9/L, with AST or ALT >= 70 IU/L and LDH >= 600 IU/L.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Class 1 and class 2 are associated with haemolysis (LDH > 600 U/L) and elevated AST ( ≥ 70 U/L) concentration"

Source for the shared class 1 and class 2 haemolysis and transaminase requirements; the class boundary itself is the platelet nadir.

Mississippi class 3 (mild / transition phase)

Platelet nadir > 100 and <= 150 x 10^9/L, with LDH > 600 U/L and AST >= 40 IU/L. Considered a transition stage capable of progression rather than a benign category.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in addition to the specific PLT count"

Source for the relaxed class-3 transaminase threshold recorded here.

Show evidence (2 references)

PMID:19245695 SUPPORT Human Clinical

"The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts."

Establishes that the Mississippi system grades severity on the platelet nadir.

PMID:19245695 SUPPORT Human Clinical

"class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in addition to the specific PLT count"

Supports the relaxed class-3 transaminase threshold recorded in this criteria set.

Notes: Because the two systems use different platelet thresholds and different transaminase cut-offs, published HELLP series are not directly comparable unless the classification used is stated - a point the source review makes explicitly about the difficulty of comparing the literature.

◈

Mechanistic Hypotheses

3

Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification

shared_placental_antiangiogenic CANONICAL

Evidence balance 2 support

HELLP shares its initiating placental lesion with preeclampsia: immune maladaptation at the maternal-fetal interface, defective trophoblast invasion, placental ischemia, and release of anti-angiogenic factors that injure the maternal endothelium. What is HELLP-specific under this model is not a different trigger but a quantitatively stronger downstream inflammatory and prothrombotic response, with soluble endoglin and Fas ligand rather than sFlt-1 carrying the differential signal, converting endothelial dysfunction into frank thrombotic microangiopathy.

This entry deliberately does not duplicate the full preeclampsia pathograph; the shared trigger is represented by a single node and the mechanistic detail of trophoblast invasion failure and sFlt-1/VEGF signaling lives on the Preeclampsia entry. The evidence below supports amplification, not a distinct upstream cause.

Pathograph links

Placental Ischemia and Anti-Angiogenic Factor Release -> Maternal Endothelial Injury and Systemic Inflammatory Amplification DIRECT Circulating anti-angiogenic factors plus placental debris injure and activate the maternal endothelium and provoke a systemic inflammatory response.

Maternal Endothelial Injury and Systemic Inflammatory Amplification -> Platelet Activation and Consumptive Thrombocytopenia DIRECT Endothelial injury with released active von Willebrand factor drives platelet adhesion, activation, and aggregation in the microvasculature.

Maternal Endothelial Injury and Systemic Inflammatory Amplification -> Microangiopathic Erythrocyte Fragmentation and Destruction DIRECT Erythrocytes are sheared as they traverse microvessels partly occluded by platelet-fibrin thrombi over a damaged endothelial surface.

Platelet Activation and Consumptive Thrombocytopenia -> Hepatic Sinusoidal Microthrombosis and Fibrin Deposition DIRECT Activated platelets participate with thrombin-generated fibrin in microthrombi that preferentially obstruct the low-shear hepatic sinusoids.

Platelet Activation and Consumptive Thrombocytopenia -> Disseminated Intravascular Coagulation and Multiorgan Failure DIRECT In roughly half of cases the same coagulation and platelet activation escalates to disseminated intravascular coagulation.

Hepatic Sinusoidal Microthrombosis and Fibrin Deposition -> Periportal Hepatocyte Necrosis and Hepatic Injury DIRECT Sinusoidal obstruction produces ischemic damage and progressive demise of hepatocytes.

Periportal Hepatocyte Necrosis and Hepatic Injury -> Disseminated Intravascular Coagulation and Multiorgan Failure INDIRECT KNOWN INTERMEDIATES Progressive hepatic failure contributes to the multiorgan decompensation of severe HELLP.

Show evidence (2 references)

PMID:23107053 SUPPORT Human Clinical

"These factors trigger the vascular endothelium, resulting in an enhanced inflammatory response which is stronger in HELLP."

States the core claim of this hypothesis - the same anti-angiogenic factors, a stronger downstream response in HELLP.

PMID:23107053 SUPPORT Human Clinical

"Maternal blood levels of anti-angiogenic sFlt1 are similar, but endoglin and Fas Ligand levels are possibly higher in HELLP than in PE."

Supports the claim that the differential signal is carried by endoglin and Fas ligand rather than sFlt-1, but is marked PARTIAL because the review itself hedges ("possibly higher"), and this entry should not report that hedge as settled.

Alternative-Complement-Pathway Two-Hit Model

complement_two_hit EMERGING

Evidence balance 2 support

On this model HELLP behaves like an aHUS-type complement-mediated thrombotic microangiopathy: a germline defect in alternative-pathway complement regulation provides the first hit, and pregnancy provides the second, permitting unrestrained terminal complement activation, C5b-9 deposition, and endothelial injury. Its strongest support is the enrichment of rare germline alternative-pathway variants and positive modified Ham testing in affected women, plus reported clinical response to C5 blockade.

Recorded as EMERGING, not CANONICAL. The genetic evidence is a single case-control study (n small, 46% vs 8%), the mHam is a functional surrogate rather than a direct measure of in vivo complement-mediated injury, and the eculizumab evidence is case reports and small series - there is no randomized trial. The complement arm should not be curated as an established causal chain, and this is the reason the C5-blockade treatment on this entry is marked as investigational.

Pathograph links

Alternative Complement Pathway Dysregulation -> Placental Ischemia and Anti-Angiogenic Factor Release DIRECT Placental C5b-9 deposition stimulates trophoblasts to secrete sFlt-1, feeding the anti-angiogenic node; complement dysregulation is therefore upstream of, not merely parallel to, the anti-angiogenic output.

Alternative Complement Pathway Dysregulation -> Maternal Endothelial Injury and Systemic Inflammatory Amplification INDIRECT KNOWN INTERMEDIATES Unrestrained terminal complement activation injures the maternal endothelium directly, in the manner of aHUS.

Maternal Endothelial Injury and Systemic Inflammatory Amplification -> Platelet Activation and Consumptive Thrombocytopenia DIRECT Endothelial injury with released active von Willebrand factor drives platelet adhesion, activation, and aggregation in the microvasculature.

Show evidence (2 references)

PMID:29563339 SUPPORT Human Clinical

"Significantly more participants with rare germline mutations in APC genes were present in the HELLP cohort compared with controls (46% versus 8%, P = 0.01)."

The primary genetic observation on which the two-hit model rests.

PMID:29563339 SUPPORT Human Clinical

"We hypothesize that HELLP syndrome follows a 2-hit disease model similar to atypical hemolytic uremic syndrome (aHUS), requiring both genetic susceptibility and an environmental risk factor."

States the two-hit framing directly, and its own wording ("We hypothesize") supports the EMERGING status assigned here.

Fetal Fatty-Acid-Oxidation-Defect Model (subset of cases)

fetal_fao_defect_maternal_liver ALTERNATIVE

Evidence balance 2 support

In a distinct subset of pregnancies, maternal HELLP or acute fatty liver of pregnancy occurs in a heterozygous carrier mother gestating a fetus with a long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or mitochondrial trifunctional protein deficiency. The proposed mechanism is that 3-hydroxy long-chain acyl intermediates accumulating in the deficient fetoplacental unit are exported into the maternal circulation and are hepatotoxic to a mother whose own beta-oxidation capacity is reduced by heterozygosity and by the metabolic demands of late pregnancy.

Applies only to a small subset and is genotype-dependent - the association tracked the common HADHA Glu474Gln (E474Q) allele and was absent in children with complete trifunctional protein deficiency. The metabolite-export mechanism itself is inferred, not directly demonstrated in the cited study, which establishes the genetic association. The corresponding fatty-acid-oxidation disorder entries (Long-Chain_3-Hydroxyacyl-CoA_Dehydrogenase_Deficiency, Mitochondrial_Trifunctional_Protein_Deficiency, Carnitine_Palmitoyltransferase_1A_Deficiency) already record this relationship from the fetal side and were deliberately not modified by this entry.

Pathograph links

Fetal Long-Chain Fatty-Acid Oxidation Defect -> Periportal Hepatocyte Necrosis and Hepatic Injury INDIRECT UNKNOWN INTERMEDIATES In this subset the maternal hepatic injury tracks the fetal LCHAD genotype rather than following from the microangiopathic chain. The edge is scoped to the alternative hypothesis group and the intervening metabolite transfer is not directly evidenced.

Show evidence (2 references)

PMID:10352164 SUPPORT Human Clinical

"While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome."

The quantitative genotype-association result that grounds this alternative model.

PMID:10352164 SUPPORT Human Clinical

"Five other children, who presented with neonatal dilated cardiomyopathy or progressive neuromyopathy, had complete deficiency of the trifunctional protein (loss of activity of all three enzymes). None had the Glu474Gln mutation, and none of their mothers had liver disease during pregnancy."

Bounds the model: the maternal association is allele-specific and did not extend to complete trifunctional protein deficiency, so this is a subset mechanism rather than a general one.

?

Discussions and Knowledge Gaps

3

Is alternative-complement-pathway dysregulation a causal driver of HELLP syndrome in the subset of women who carry germline variants, or a bystander marker of the severe endothelial injury that HELLP shares with other thrombotic microangiopathies?

KNOWLEDGE GAP OPEN hellp_complement_causal_role

Attached to

pathophysiology#Alternative Complement Pathway Dysregulation

The evidence is suggestive but does not settle direction. Germline alternative-pathway variants are enriched in HELLP cohorts and modified Ham testing is frequently positive, but the study is a single case-control series, complement activation is expected downstream of any severe endothelial injury, and the therapeutic evidence for C5 blockade is uncontrolled case reports in a condition that resolves on delivery. Resolving this determines whether eculizumab belongs on this entry as a treatment or only as a hypothesis.

Proposed experiments

Randomized trial of C5 blockade in early-onset HELLP

hellp_c5_blockade_rct

A randomized trial of eculizumab or ravulizumab versus expectant management plus standard care in HELLP remote from term, with pregnancy prolongation and maternal organ-injury markers as endpoints, stratified by germline alternative-pathway genotype and baseline mHam status.

Replication of the germline variant enrichment in an independent cohort

hellp_apc_variant_replication

Independent case-control sequencing of alternative-pathway complement genes in HELLP versus normotensive pregnancy and versus severe preeclampsia without HELLP, to test whether the enrichment is specific to HELLP or general to severe hypertensive disease of pregnancy.

Show evidence (1 reference)

PMID:32986992 SUPPORT Human Clinical

"These findings suggest that the inhibition of the terminal complement pathway, possibly through C5 blockade, may be an effective strategy to treat preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, but this strategy warrants further evaluation in clinical trials."

The source's own statement that trial evaluation is still required, which is the gap this discussion records.

Is HELLP a severe variant within the preeclampsia spectrum, or a distinct disease entity that merely co-occurs with preeclampsia?

CONTROVERSY OPEN hellp_distinct_entity_or_pe_variant

Attached to

pathophysiology#Maternal Endothelial Injury and Systemic Inflammatory Amplification

This is not a naming argument - it determines whether HELLP-specific mechanism nodes are warranted at all. Arguments for a variant: 70-80% of cases coexist with preeclampsia, the placental trigger appears shared, and ICD-10 codes HELLP as a subcode of preeclampsia (O14.2), which makes "HELLP without PE" unascertainable in administrative data. Arguments for a distinct entity: risk-factor profiles diverge (diabetes, chronic hypertension, and obesity track isolated preeclampsia while chronic inflammatory disease and lupus track HELLP), outcome dynamics diverge, and the liver-dominant thrombotic microangiopathy has no counterpart in uncomplicated preeclampsia. This entry takes the operational position of curating HELLP separately while modeling the shared upstream in a single compressed node.

Show evidence (3 references)

PMID:42502666 SUPPORT Human Clinical

"iPE and PE with HELLP differ regarding their risk factors and types and dynamics of their major complications."

Population-scale evidence for divergence, the strongest current argument for treating HELLP as more than a severity label.

PMID:42502666 SUPPORT Human Clinical

"However, whether it represents a distinct condition or a severe variant within the PE spectrum has been debated."

The source explicitly frames this as an unresolved debate rather than a settled question.

PMID:23107053 SUPPORT Human Clinical

"HELLP occurs in 0.2-0.8% of pregnancies and in 70-80% of cases it coexists with preeclampsia (PE)."

The high but incomplete coexistence rate is evidence on both sides: it supports the shared-spectrum view while leaving 20-30% of cases without preeclampsia.

Are 3-hydroxy long-chain acyl metabolites actually transferred from an LCHAD-deficient fetoplacental unit into the maternal circulation at hepatotoxic concentrations, or is the maternal liver injury explained by some other consequence of the fetal genotype?

KNOWLEDGE GAP OPEN hellp_fao_metabolite_transfer

Attached to

pathophysiology#Fetal Long-Chain Fatty-Acid Oxidation Defect

The genetic association is strong and allele-specific, but the mechanistic step routinely quoted for it - placental export of toxic 3-hydroxy intermediates into a heterozygous mother with reduced beta-oxidation reserve - is an inference. The cited study establishes genotype-phenotype correlation, not metabolite transfer. The causal edge from this node is therefore typed INDIRECT_UNKNOWN_INTERMEDIATES.

Proposed experiments

Maternal acylcarnitine profiling stratified by fetal genotype

hellp_maternal_acylcarnitine_profiling

Serial maternal plasma long-chain 3-hydroxyacylcarnitine measurement across the third trimester in pregnancies stratified by fetal HADHA/HADHB genotype, testing whether maternal metabolite concentrations rise before and track with maternal hepatic injury.

Show evidence (1 reference)

PMID:10352164 SUPPORT Human Clinical

"Women with acute liver disease during pregnancy may have a Glu474Gln mutation in long-chain hydroxyacyl-CoA dehydrogenase."

The study's own conclusion is stated as a genetic association; it does not assert metabolite transfer, which is the gap recorded here.

⚙

Pathophysiology

9

Placental Ischemia and Anti-Angiogenic Factor Release

The initiating lesion is shared with preeclampsia: immune maladaptation toward the invading trophoblast, defective spiral-artery remodeling, and placental malperfusion, followed by release of anti-angiogenic factors (sFlt-1, soluble endoglin) together with placental necrotic debris and cell-free DNA into the maternal circulation. This node is deliberately compressed - the trophoblast-invasion and sFlt-1/VEGF detail is curated on the Preeclampsia entry and is not re-derived here. What matters for HELLP is that the placental output includes an inflammatory as well as an anti-angiogenic component.

Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification

trophoblast cell CL:0000351

angiogenesis GO:0001525 ↓ DECREASED vascular endothelial growth factor receptor signaling pathway GO:0048010 ↓ DECREASED

Downstream

Maternal Endothelial Injury and Systemic Inflammatory Amplification Circulating anti-angiogenic factors plus placental debris injure and activate the maternal endothelium and provoke a systemic inflammatory response.

Show evidence (3 references)

PMID:23107053 SUPPORT Human Clinical

"Immunological maladaptation is the most probable trigger of the insult to the invading trophoblast."

Establishes the shared upstream trophoblast insult as the probable trigger in HELLP.

PMID:23107053 SUPPORT Human Clinical

"Anti-angiogenic factors released into maternal blood induce the maternal syndromes."

Links the placental lesion to release of anti-angiogenic factors as the effector output of this node.

PMID:31877439 SUPPORT Human Clinical

"The placenta releases, besides anti-angiogenetic factors, also necrotic debris and cell-free DNA, a mixture that not only induces systemic endothelial dysfunction as in preeclampsia, but also a systemic inflammatory response."

Supports the HELLP-specific addition to this node - a co-released inflammatory component beyond the anti-angiogenic factors.

Alternative Complement Pathway Dysregulation

In a substantial subset of women, rare germline variants in alternative-pathway complement genes reduce complement regulation, and pregnancy acts as the second hit permitting unrestrained terminal-pathway activation. Placental C5b-9 deposition is increased, and C5b-9 in turn stimulates trophoblast sFlt-1 secretion, so this arm both parallels and feeds back onto the anti-angiogenic node above. This node is modeled as a parallel, hypothesis-scoped trigger rather than part of the canonical chain.

Alternative-Complement-Pathway Two-Hit Model

trophoblast cell CL:0000351

complement activation, alternative pathway GO:0006957 ↑ INCREASED complement activation GO:0006956 ↕ DYSREGULATED

Downstream

Placental Ischemia and Anti-Angiogenic Factor Release Placental C5b-9 deposition stimulates trophoblasts to secrete sFlt-1, feeding the anti-angiogenic node; complement dysregulation is therefore upstream of, not merely parallel to, the anti-angiogenic output.

Maternal Endothelial Injury and Systemic Inflammatory Amplification Unrestrained terminal complement activation injures the maternal endothelium directly, in the manner of aHUS.

Show evidence (2 references)

PMID:29563339 SUPPORT Human Clinical

"HELLP syndrome is characterized by both activation of the APC and frequent germline mutations in APC genes."

Directly supports both components of this node - functional alternative-pathway activation and germline predisposing variants.

PMID:32986992 SUPPORT Human Clinical

"In women who develop preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, there is a shift toward increased complement activation and decreased complement regulation."

Independent review support for loss of complement regulation as a feature of HELLP.

Fetal Long-Chain Fatty-Acid Oxidation Defect

In a small, genotype-defined subset, the fetus is homozygous or compound heterozygous for a long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency allele, classically HADHA Glu474Gln, while the mother is an obligate heterozygote. Accumulating 3-hydroxy long-chain acyl intermediates in the fetoplacental unit are proposed to reach the maternal circulation and injure a maternal liver whose own beta-oxidation reserve is reduced. The genetic association is well established; the metabolite-transfer step is inferred rather than directly measured.

Fetal Fatty-Acid-Oxidation-Defect Model (subset of cases)

HADHA hgnc:4801

Downstream

Periportal Hepatocyte Necrosis and Hepatic Injury In this subset the maternal hepatic injury tracks the fetal LCHAD genotype rather than following from the microangiopathic chain. The edge is scoped to the alternative hypothesis group and the intervening metabolite transfer is not directly evidenced.

Show evidence (1 reference)

PMID:10352164 SUPPORT Human Clinical

"Acute fatty liver of pregnancy and the HELLP syndrome (hemolysis, elevated liver-enzyme levels, and a low platelet count) are serious hepatic disorders that may occur during pregnancy in women whose fetuses are later found to have a deficiency of long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase."

Establishes the fetal-genotype-to-maternal-liver-disease association that defines this node.

Maternal Endothelial Injury and Systemic Inflammatory Amplification

Circulating placental factors activate and injure the maternal vascular endothelium and provoke a systemic inflammatory response with activated leukocytes, inflammatory cytokines, and active von Willebrand factor. In HELLP this inflammatory amplification is stronger than in preeclampsia, and it is the step at which the shared preeclamptic endothelial dysfunction is converted into an overtly prothrombotic microvascular state.

Alternative-Complement-Pathway Two-Hit Model Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification

blood vessel endothelial cell CL:0000071

endothelial cell activation GO:0042118 ↑ INCREASED inflammatory response GO:0006954 ↑ INCREASED

Downstream

Platelet Activation and Consumptive Thrombocytopenia Endothelial injury with released active von Willebrand factor drives platelet adhesion, activation, and aggregation in the microvasculature.

Microangiopathic Erythrocyte Fragmentation and Destruction Erythrocytes are sheared as they traverse microvessels partly occluded by platelet-fibrin thrombi over a damaged endothelial surface.

Show evidence (2 references)

PMID:23107053 SUPPORT Human Clinical

"These factors trigger the vascular endothelium, resulting in an enhanced inflammatory response which is stronger in HELLP."

Directly supports endothelial triggering plus the HELLP-specific amplification asserted by this node.

PMID:31877439 SUPPORT Human Clinical

"The latter aggravates the endothelio-toxic effects in the systemic cardiovascular bed, amplifying the already increased pro-thrombotic conditions."

Supports the conversion of endothelial injury into a systemic prothrombotic state, the defining output of this node.

Platelet Activation and Consumptive Thrombocytopenia

Platelets adhere to and are activated on the injured endothelium and are consumed into microvascular platelet-fibrin thrombi. The thrombocytopenia of HELLP is therefore consumptive rather than a production failure - which is why platelet nadir is used as the severity axis of the Mississippi classification, and why platelet transfusion is reserved for bleeding or the most severe class rather than used to correct the count.

Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification

platelet CL:0000233

platelet activation GO:0030168 ↑ INCREASED

Downstream

Hepatic Sinusoidal Microthrombosis and Fibrin Deposition Activated platelets participate with thrombin-generated fibrin in microthrombi that preferentially obstruct the low-shear hepatic sinusoids.

Disseminated Intravascular Coagulation and Multiorgan Failure In roughly half of cases the same coagulation and platelet activation escalates to disseminated intravascular coagulation.

Show evidence (1 reference)

PMID:23107053 SUPPORT Human Clinical

"The angiopathy results in consumption of circulating platelets, causes hemolysis in affected microvessels and reduces portal blood flow in the liver."

Establishes that circulating platelets are consumed by the microangiopathy, the consumptive mechanism this node asserts.

Microangiopathic Erythrocyte Fragmentation and Destruction

Erythrocytes are mechanically fragmented as they are forced across partly occluded microvessels, producing schistocytes on the peripheral smear, intravascular hemolysis with raised LDH and indirect bilirubin, and consumed haptoglobin. This is the "H" of HELLP and is the extrinsic, mechanical arm of the conserved hemolytic-anemia destruction pathway - the erythrocyte itself is normal, the insult is the vessel.

erythrocyte CL:0000232

Show evidence (2 references)

PMID:23107053 SUPPORT Human Clinical

"The angiopathy results in consumption of circulating platelets, causes hemolysis in affected microvessels and reduces portal blood flow in the liver."

Establishes that erythrocyte destruction in HELLP occurs within the affected microvessels, i.e. is mechanical and microangiopathic, which is the specialization this node makes on the generic hemolytic-anemia destruction node.

PMID:15121574 SUPPORT Human Clinical

"The diagnosis of HELLP syndrome requires the presence of hemolysis based on examination of the peripheral smear, elevated indirect bilirubin levels, or low serum haptoglobin levels"

Supports the laboratory signature of intravascular erythrocyte destruction named in this node.

Hepatic Sinusoidal Microthrombosis and Fibrin Deposition

The uniquely low shear of the hepatic sinusoids makes them the preferential site for microthrombus formation and fibrin deposition, producing a sinusoidal obstruction physiologically analogous to sinusoidal obstruction syndrome, with reduced portal inflow and sinusoidal ischemia. This is the hepatic, site-selective step that converts a systemic microangiopathy into the liver-dominant clinical picture of HELLP.

Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification

endothelial cell of hepatic sinusoid CL:1000398 platelet CL:0000233

blood coagulation, fibrin clot formation GO:0072378 ↑ INCREASED blood coagulation GO:0007596 ↑ INCREASED

Downstream

Periportal Hepatocyte Necrosis and Hepatic Injury Sinusoidal obstruction produces ischemic damage and progressive demise of hepatocytes.

Show evidence (2 references)

PMID:31877439 SUPPORT Human Clinical

"Particularly in microcirculations with extremely low shear forces, such as in the hepatic sinusoids, this will facilitate microthrombi formation and fibrin deposition eventually resulting in obstruction of the sinusoids similar as in SOS."

The direct statement of platelet-assisted fibrin thrombus formation at a defined vascular site, which is what qualifies this node for branch-level conformance to the thrombogenesis module.

PMID:11924711 SUPPORT Human Clinical

"hepatic haemorrhages sharply demarcated by an extended fibrin network from the surrounding unaffected liver parenchyma"

Autopsy confirmation of intrahepatic fibrin deposition in fatal HELLP, i.e. the formed fibrin structure rather than an inferred prothrombotic state.

Periportal Hepatocyte Necrosis and Hepatic Injury

Hepatocytes die by ischemic (coagulation) necrosis in a characteristically periportal distribution, releasing AST and ALT into the maternal circulation - the "EL" of HELLP. Two routes converge here: sinusoidal ischemia downstream of microthrombosis, and direct hepatocyte death signaling attributed to placental Fas ligand. The resulting confluent necrosis and intrahepatic hemorrhage are what underlie hepatic capsular distension, subcapsular hematoma, and, rarely, liver rupture.

Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification

hepatocyte CL:0000182

hepatocyte apoptotic process GO:0097284 ↑ INCREASED extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 ↑ INCREASED

Downstream

Disseminated Intravascular Coagulation and Multiorgan Failure Progressive hepatic failure contributes to the multiorgan decompensation of severe HELLP.

Show evidence (2 references)

PMID:23107053 SUPPORT Human Clinical

"Placental Fas Ligand damages hepatocytes, resulting in periportal necrosis."

Supports the death-receptor route to periportal hepatocyte necrosis represented by this node.

PMID:11924711 SUPPORT Human Clinical

"We found an almost identical histopathological pattern in the liver (periportal coagulation necrosis"

Autopsy evidence that periportal coagulation necrosis is the reproducible hepatic lesion of fatal HELLP.

Disseminated Intravascular Coagulation and Multiorgan Failure

In about half of women with HELLP, coagulation factor and platelet activation precipitates disseminated intravascular coagulation; in a minority this becomes uncompensated and drives life-threatening multiorgan failure. This node is the organism-scale terminus of the entry.

blood coagulation GO:0007596 ↕ DYSREGULATED

Show evidence (1 reference)

PMID:23107053 SUPPORT Human Clinical

"In about one half of women with HELLP, activation of coagulation factors and platelets precipitates disseminated intravascular coagulation, which in a minority becomes uncompensated and contributes to life-threatening multiorgan failure."

Establishes both the frequency of DIC and its role in the fatal multiorgan endpoint.

✶

Histopathology

2

Periportal hepatic coagulation necrosis

Coagulative necrosis in a periportal distribution, with intrahepatic hemorrhages demarcated by an extended fibrin network, focal sinusoidal leukostasis, and Kupffer cell swelling. Notably there is no inflammatory infiltrate in the liver plates and no fatty change - the latter is the key histological discriminator from acute fatty liver of pregnancy.

Show evidence (2 references)

PMID:11924711 SUPPORT Human Clinical

"We found an almost identical histopathological pattern in the liver (periportal coagulation necrosis, hepatic haemorrhages sharply demarcated by an extended fibrin network from the surrounding unaffected liver parenchyma, focal leukostasis in liver sinusoids and swelling of Kupffer's cells,..."

Full description of the reproducible hepatic lesion across three fatal cases, including the absence of fatty change that separates HELLP from acute fatty liver of pregnancy.

PMID:23107053 SUPPORT Human Clinical

"Placental Fas Ligand damages hepatocytes, resulting in periportal necrosis."

Independent statement that periportal necrosis is the characteristic hepatic lesion of HELLP.

Glomerular endothelial swelling with bloodless glomeruli

The renal lesion in fatal HELLP: bloodless glomeruli with swollen, vacuolated intracapillary cells, cigar-shaped capillary loops, enlarged tufts herniating into the proximal convoluted tubule, and mesangial cell swelling. This is a renal thrombotic microangiopathy pattern rather than an inflammatory glomerulonephritis.

Show evidence (1 reference)

PMID:11924711 SUPPORT Human Clinical

"kidneys (bloodless glomeruli with swollen and vacuolated intracapillary cells, cigar-shaped capillary loops, enlarged glomerular tufts with herniation of capillary loops into the proximal convoluted tubules, swelling of mesangial cells)"

Describes the reproducible renal histopathology observed in fatal HELLP.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

22

Blood 3

Microangiopathic hemolytic anemia OBLIGATE HP:0001878

Show evidence (1 reference)

PMID:15121574 SUPPORT Human Clinical

"The diagnosis of HELLP syndrome requires the presence of hemolysis based on examination of the peripheral smear, elevated indirect bilirubin levels, or low serum haptoglobin levels in association with significant elevation in liver enzymes and a platelet count below 100,000/mm(3) after ruling..."

Hemolysis is a required diagnostic criterion, which is the basis for the OBLIGATE frequency assigned here.

Thrombocytopenia OBLIGATE HP:0001873

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

The platelet threshold is a required diagnostic criterion, supporting the OBLIGATE frequency.

Disseminated intravascular coagulation FREQUENT HP:0005521

Show evidence (1 reference)

PMID:23107053 SUPPORT Human Clinical

"In about one half of women with HELLP, activation of coagulation factors and platelets precipitates disseminated intravascular coagulation"

"About one half" maps to the FREQUENT (30-79%) band and is a direct quantitative statement, satisfying the frequency-evidence requirement.

Cardiovascular 1

Hypertension FREQUENT HP:0000822

Show evidence (2 references)

PMID:19245695 SUPPORT Human Clinical

"hypertension and proteinuria, which may be absent in 10–20% of the cases"

The review states the majority have hypertension and proteinuria but that these may be absent in 10-20% of cases, supporting a FREQUENT rather than OBLIGATE band.

PMID:7055180 SUPPORT Human Clinical

"This entity has been termed the HELLP syndrome and may occur when the usual clinical findings to diagnose severe preeclampsia are absent."

The original description already recorded that the usual preeclampsia findings may be absent.

Digestive 2

Nausea and vomiting VERY_FREQUENT HP:0002017

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Typical clinical symptoms are right upper abdominal quadrant or epigastric pain, nausea and vomiting."

Names nausea and vomiting among the same list of typical clinical symptoms. "Typical" maps to VERY_FREQUENT under Pattern C of docs/frequency-evidence-guidelines.md; because this band rests on the identical sentence as the epigastric-pain band, the two are held equal rather than split on an unevidenced distinction.

Ascites HP:0001541

No frequency band is asserted, for the same reason recorded on placental abruption: Table 3 reports severe ascites at 4-11% but that row is under the five-word evidence minimum and cannot be joined to its neighbours. Had it been quotable the band would be OCCASIONAL - the published range straddles the VERY_RARE/OCCASIONAL boundary at 5%, and both the midpoint (7.5%) and most of the interval sit above it. Revisit if a single-cohort figure in prose becomes available.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"severe ascites, abruptio placentae, oliguria, pulmonary oedema or eclampsia"

Names severe ascites among the severe maternal complications of HELLP that are indications for immediate delivery.

Genitourinary 2

Proteinuria FREQUENT HP:0000093

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"hypertension and proteinuria, which may be absent in 10–20% of the cases"

Same source and reasoning as for hypertension; supports FREQUENT rather than OBLIGATE.

Acute kidney injury HP:0001919

Show evidence (1 reference)

PMID:42502666 SUPPORT Human Clinical

"HELLP syndrome is associated with a higher burden of multiorgan involvement, including acute kidney injury and severe hematological and hepatic conditions."

Directly associates HELLP with acute kidney injury as part of its multiorgan burden.

Metabolism 1

Pulmonary edema HP:0100598

No frequency band is asserted, for the same reason recorded on placental abruption: Table 3 reports pulmonary oedema at 3-10% but that row is under the five-word evidence minimum and cannot be joined to its neighbours. The figure is kept in the description.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"severe ascites, abruptio placentae, oliguria, pulmonary oedema or eclampsia"

Names pulmonary oedema among the severe maternal complications of HELLP that are indications for immediate delivery.

Nervous System 2

Headache FREQUENT HP:0002315

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Up to 30–60% of women have headache"

Gives the 30-60% headache figure that maps to the FREQUENT (30-79%) band. The cached source is a hard-wrapped PDF extraction and the clause continues onto the next physical line as "have headache; about 20% visual symptoms", so the sentence cannot be quoted whole; the quoted fragment is the half that carries the number this band rests on.

Eclamptic seizures OCCASIONAL HP:0001250

An earlier revision took this band from the 4-9% row of Table 3 in PMID:19245695. That row agrees but is a table cell too short to quote as evidence, and padding it out with the table's header row would satisfy the word counter while leaving exactly the unverifiable-table-cell citation that guard exists to prevent. The cohort figure is quoted instead; it is also a single population rather than a pooled range, so no band-straddle caveat is needed.

Show evidence (1 reference)

PMID:42502666 SUPPORT Human Clinical

"Among women who had PE-HELLP, 10.5% had gestational diabetes, 45.1% had an early PE, 6.5% had an eclampsia"

A directly reported eclampsia rate of 6.5% among women with PE-HELLP in a 2.8-million-pregnancy cohort, which sits in the OCCASIONAL (5-29%) band.

Prenatal and Birth 1

Preterm birth FREQUENT Premature birth HP:0001622

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Preterm delivery4 70 (15% < 28 gestational weeks)"

A directly reported preterm-delivery rate of 70% (the trailing "4" is the source table's footnote marker), which maps to the FREQUENT (30-79%) band. This replaces an earlier inference from onset timing, which stated when HELLP begins rather than how often delivery is preterm.

Growth 1

Fetal growth restriction FREQUENT Intrauterine growth retardation HP:0001511

Show evidence (2 references)

PMID:42502666 SUPPORT Human Clinical

"After PE-HELLP, 51.2% of children were small for gestational age, 64.5% were preterm, and 0.4% died in utero or after birth."

A directly reported small-for-gestational-age rate of 51.2% after PE-HELLP in a nationwide French cohort, which maps to the FREQUENT (30-79%) band. Preferred over the review's 38-61% complication-table row, which agrees but is a table cell too short to quote as evidence.

PMID:35475405 SUPPORT Human Clinical

"Some outcomes overlapped because FGR commonly complicated PE and HELLP syndrome."

Documents frequent co-occurrence of fetal growth restriction with HELLP in a high-risk cohort.

Other 9

Schistocytes on peripheral blood smear Schistocytosis HP:0001981

Show evidence (1 reference)

PMID:15121574 SUPPORT Human Clinical

"hemolysis based on examination of the peripheral smear"

Names peripheral smear examination as a route to documenting the hemolysis criterion.

Elevated serum aspartate aminotransferase OBLIGATE Elevated circulating aspartate aminotransferase concentration HP:0031956

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

AST elevation is a required diagnostic criterion, supporting the OBLIGATE frequency.

Elevated serum alanine aminotransferase Elevated circulating alanine aminotransferase concentration HP:0031964

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in addition to the specific PLT count"

The Mississippi criteria admit AST or ALT interchangeably at the same threshold, supporting ALT elevation as a recognized manifestation.

Hepatic subcapsular hematoma and liver rupture VERY_RARE HP:6000998

Hematoma and rupture are recorded as one phenotype rather than split, because the HPO term used here defines liver rupture explicitly in terms of subcapsular hematoma formation ("characterized by the development of a hematoma, often quite large, beneath the liver capsule"). The `preferred_term` names both so the entry does not read as covering only the rupture endpoint.

Show evidence (2 references)

PMID:19245695 SUPPORT Human Clinical

"Subcapsular liver hematoma Between 0.9% and <2%"

The review's complication table reports subcapsular liver hematoma between 0.9% and under 2% of HELLP cases, which maps to the VERY_RARE (1-4%) band. The double space after "Between" is present in the cached source.

PMID:19245695 SUPPORT Human Clinical

"Liver rupture >200 cases or about 1.8%"

The same table reports frank liver rupture at about 1.8%, also within the VERY_RARE band.

Elevated lactate dehydrogenase OBLIGATE Increased circulating lactate dehydrogenase concentration HP:0025435

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

Names LDH above 600 U/L as one of the three required Tennessee criteria, which is the direct support for the OBLIGATE frequency band.

Reduced haptoglobin Reduced haptoglobin level HP:0020181

Show evidence (1 reference)

PMID:15121574 SUPPORT Human Clinical

"or low serum haptoglobin levels in association with significant elevation in liver enzymes"

Names low serum haptoglobin as an accepted marker of the hemolysis required for diagnosis.

Hyperbilirubinemia HP:0002904

Show evidence (1 reference)

PMID:15121574 SUPPORT Human Clinical

"The diagnosis of HELLP syndrome requires the presence of hemolysis based on examination of the peripheral smear, elevated indirect bilirubin levels, or low serum haptoglobin levels"

Names elevated indirect bilirubin as an accepted marker of the hemolysis criterion.

Right upper quadrant or epigastric pain VERY_FREQUENT HP:0410019

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Typical clinical symptoms are right upper abdominal quadrant or epigastric pain, nausea and vomiting."

Names right upper quadrant/epigastric pain first among the typical clinical symptoms of HELLP. "Typical" maps to VERY_FREQUENT under Pattern C (qualitative-term mapping) of docs/frequency-evidence-guidelines.md.

Placental abruption HP:0011419

No frequency band is asserted. Table 3 of the same review reports abruptio placentae at 9-20%, which would be OCCASIONAL, but that table row cannot be quoted as evidence: it is under the five-word minimum for an evidence snippet, and the rows cannot be joined because the trailing citation bracket is stripped from the snippet but not from the cached text. Per CLAUDE.md the band is omitted rather than hung on a quote that does not state it; the figure is retained in the description.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"severe ascites, abruptio placentae, oliguria, pulmonary oedema or eclampsia"

Names abruptio placentae among the severe maternal complications of HELLP that are indications for immediate delivery.

🧬

Genetic Associations

2

Alternative complement pathway genes

relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (2 references)

PMID:29563339 SUPPORT Human Clinical

"Significantly more participants with rare germline mutations in APC genes were present in the HELLP cohort compared with controls (46% versus 8%, P = 0.01)."

The case-control enrichment that grounds a SUSCEPTIBILITY rather than causal classification.

PMID:23107053 SUPPORT Human Clinical

"No single world-wide genetic cause for excessive risk of HELLP or PE has been identified."

Explicitly rules out a monogenic architecture, supporting the polygenic/susceptibility framing.

HADHA (fetal genotype)

Gene: HADHA hgnc:4801 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (1 reference)

PMID:10352164 SUPPORT Human Clinical

"While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome."

The fetal-genotype-conditioned maternal risk that defines this entry.

💊

Medical Actions

7

Delivery of the fetus and placenta

Action: Induction of Labor NCIT:C92814

The only definitive treatment. Removing the placenta removes the source of the anti-angiogenic and inflammatory drive, and the syndrome resolves. Delivery is indicated once the 34th gestational week is reached, or at any gestation if maternal or fetal condition deteriorates; before 34 weeks a short expectant interval may be taken to complete fetal lung maturation.

Mechanism Target:

INHIBITS Placental Ischemia and Anti-Angiogenic Factor Release — Delivery of the placenta physically removes the organ generating the anti-angiogenic and inflammatory output that drives the entire cascade.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Delivery is indicated if the HELLP syndrome occurs after the 34th gestational week or the foetal and/or maternal conditions deteriorate."

Establishes delivery as the intervention of record and states its timing indication.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Vaginal delivery is preferable. If the cervix is unfavourable, it is reasonable to induce cervical ripening and then labour."

Supports induction of labour with vaginal delivery as the preferred route.

Cesarean delivery

Action: Cesarean Section NCIT:C46088

Used when vaginal delivery is not feasible or maternal or fetal deterioration demands immediate delivery. Recorded separately from induction because the two are different procedures with different risk profiles in a thrombocytopenic patient.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Vaginal delivery is preferable. If the cervix is unfavourable, it is reasonable to induce cervical ripening and then labour."

Supports cesarean as the non-preferred alternative route. Marked PARTIAL because the quoted guidance states the preference for vaginal delivery rather than the indications for cesarean.

Antenatal corticosteroid therapy

Action: Pharmacotherapy NCIT:C15986

Agent: dexamethasone CHEBI:41879 betamethasone CHEBI:3077

Betamethasone or dexamethasone, given between 24 and 34 weeks primarily for fetal lung maturation. Its value for the maternal syndrome is a genuine controversy and this entry does not resolve it: a Cochrane review of 11 trials found improved platelet counts (dexamethasone more than betamethasone) but no clear effect on maternal death, severe maternal morbidity, or perinatal death, and concluded there is insufficient evidence for routine use.

Target Phenotypes: Thrombocytopenia HP:0001873

Show evidence (3 references)

PMID:20824872 SUPPORT Human Clinical

"The only clear effect of treatment on individual outcomes was improved platelet count (standardized mean difference (SMD) 0.67, 95% CI 0.24 to 1.10)."

Quantifies the one demonstrated maternal effect - a platelet-count improvement - and, by naming it as the only clear effect, is PARTIAL support for corticosteroids as a treatment of the maternal syndrome.

PMID:20824872 REFUTE Human Clinical

"There is to date insufficient evidence of benefits in terms of substantive clinical outcomes to support the routine use of steroids for the management of HELLP."

Refutes routine corticosteroid use for the maternal syndrome. Retained deliberately alongside the supporting item so the entry records the controversy rather than picking a side.

PMID:19245695 SUPPORT Human Clinical

"Standard corticosteroid treatment is, however, of uncertain clinical value in the maternal HELLP syndrome."

Independent review agreement that the maternal benefit is uncertain, while fetal lung maturation remains the accepted indication.

Magnesium sulfate seizure prophylaxis

Action: Anticonvulsant Therapy NCIT:C64172

Agent: magnesium sulfate CHEBI:32599

Given to prevent eclamptic seizures, which complicate 4-9% of HELLP pregnancies. Prophylaxis is standard in HELLP even when hypertension is mild or absent, because seizure risk does not track blood pressure in this syndrome.

Target Phenotypes: Eclamptic seizure HP:0001250

Show evidence (1 reference)

PMID:42502666 SUPPORT Human Clinical

"Among women who had PE-HELLP, 10.5% had gestational diabetes, 45.1% had an early PE, 6.5% had an eclampsia"

Quantifies the eclampsia risk that seizure prophylaxis addresses: 6.5% of women with PE-HELLP had an eclampsia in a nationwide cohort.

Antihypertensive therapy

Action: Antihypertensive Therapy NCIT:C172184

Blood pressure control targeting below 155/105 mmHg, to reduce the risk of maternal stroke and abruption while the definitive intervention is arranged.

Target Phenotypes: Hypertension HP:0000822

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Blood pressure should be kept below 155/105 mmHg."

States the blood-pressure target this treatment implements.

Platelet transfusion

Action: Platelet Transfusion NCIT:C15366

Reserved for active bleeding or the most severe (Mississippi class 1) disease around delivery. Because the thrombocytopenia is consumptive, transfusion corrects the count only transiently and is not used to normalize a number.

Target Phenotypes: Thrombocytopenia HP:0001873

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In a recent study of women with class 1 HELLP syndrome adding of platelet transfusion to standard CS administration did not increase the recovery rate"

The review discusses platelet transfusion specifically in the context of class 1 HELLP, supporting the restricted indication recorded here.

Terminal complement (C5) blockade with eculizumab

Action: Pharmacotherapy NCIT:C15986

Agent: eculizumab NCIT:C48386

INVESTIGATIONAL. A monoclonal antibody against complement C5, used off-label in reported cases of severe early preeclampsia/HELLP on the rationale that HELLP is an aHUS-like complement-mediated microangiopathy. In one reported case at 26 weeks it produced marked clinical improvement, normalized laboratory parameters, and prolonged pregnancy by 17 days. There is no randomized trial evidence, and this entry records it as an open question rather than as standard care.

Mechanism Target:

INHIBITS Alternative Complement Pathway Dysregulation — Blockade of C5 prevents formation of the terminal C5b-9 complex, the effector of the complement arm modeled by this node.

Show evidence (1 reference)

PMID:32986992 SUPPORT Human Clinical

"These findings suggest that the inhibition of the terminal complement pathway, possibly through C5 blockade, may be an effective strategy to treat preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, but this strategy warrants further evaluation in clinical trials."

Supports the mechanistic rationale for C5 blockade while explicitly stating that clinical-trial evaluation is still required, which is why this link is PARTIAL.

Show evidence (1 reference)

PMID:23228435 SUPPORT Human Clinical

"We describe a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters."

A single-patient report of clinical and laboratory response. Marked PARTIAL because an uncontrolled n-of-1 observation in a self-limiting-on-delivery condition cannot establish efficacy.

🔬

Biochemical Markers

5

Serum lactate dehydrogenase (INCREASED)

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

Gives the diagnostic LDH threshold used in this record.

Serum aspartate aminotransferase (INCREASED)

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."

Gives the diagnostic AST threshold used in this record.

Platelet count (DECREASED)

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts."

Supports the use of platelet nadir as the severity axis described here.

Serum haptoglobin (DECREASED)

Show evidence (1 reference)

PMID:15121574 SUPPORT Human Clinical

"or low serum haptoglobin levels in association with significant elevation in liver enzymes"

Names low haptoglobin as an accepted marker of the required hemolysis.

Soluble endoglin (INCREASED)

Show evidence (3 references)

PMID:35475405 SUPPORT Human Clinical

"Higher levels were observed in HELLP syndrome and EOPE cases."

Direct observation of raised sFlt-1/PlGF and soluble endoglin in HELLP cases.

PMID:35475405 SUPPORT Human Clinical

"0.895 (95%-Cl 0.83-0.96) and 0.878 (95%-Cl 0.81-0.95) in HELLP syndrome"

Quantifies detection performance of the sFlt-1/PlGF ratio and soluble endoglin for HELLP.

PMID:23107053 SUPPORT Human Clinical

"Maternal blood levels of anti-angiogenic sFlt1 are similar, but endoglin and Fas Ligand levels are possibly higher in HELLP than in PE."

Supports the HELLP-versus-preeclampsia differential for endoglin, but is marked PARTIAL because the source itself hedges with "possibly".

📈

Progression

3

Antepartum onset

Age: Usually 27-37 weeks of gestation

About 70% of cases present before delivery, with a peak between the 27th and 37th gestational weeks; onset is usually rapid and the syndrome characteristically exacerbates overnight.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"About 70% of the cases develop before delivery, the majority between the 27th and 37th gestational weeks; the remainder within 48 hours after delivery."

Establishes the antepartum timing and its peak gestational window.

Postpartum onset

Age: Within 48 hours of delivery

The remaining ~30% of cases declare themselves postpartum, typically within 48 hours, most often in women who already had hypertension and proteinuria before delivery. Maternal surveillance is therefore continued for at least 48 hours after delivery.

Show evidence (2 references)

PMID:19245695 SUPPORT Human Clinical

"About 70% of the cases develop before delivery, the majority between the 27th and 37th gestational weeks; the remainder within 48 hours after delivery."

The complement of the antepartum fraction defines the postpartum-onset window.

PMID:19245695 SUPPORT Human Clinical

"Close surveillance of the mother should be continued for at least 48 hours after delivery."

Supports the 48-hour postpartum surveillance window implied by this phase.

Subsequent pregnancies

Age: Later pregnancies after an index HELLP pregnancy

After an index HELLP pregnancy the risk of obstetric complications in later pregnancies is high, but the risk of recurrent HELLP specifically is low (3-6% across two cohorts). This asymmetry is mechanistically informative: the shared placental susceptibility recurs far more readily than the full microangiopathic escalation.

Show evidence (2 references)

PMID:7847520 SUPPORT Human Clinical

"Complications included preeclampsia (19%), preterm delivery (21%), intrauterine growth restriction (12%), abruptio placentae (2%), perinatal death (4%), and HELLP syndrome (3%)."

Quantifies subsequent-pregnancy complication rates and the 3% HELLP recurrence rate in normotensive women.

PMID:12824985 SUPPORT Human Clinical

"Recurrent hemolysis, elevated liver enzymes, and low platelet count syndrome developed in 4 of these pregnancies (6%)"

Confirms a low (6%) HELLP recurrence rate even in the severe early-onset subgroup.

📊

Prevalence

3

Pregnancies, general obstetric population

Period Prevalence 500.0–900.0 per 100,000 >1 in 1,000

0.5-0.9% of all pregnancies, i.e. 500-900 per 100,000 pregnancies. Modeled as a period prevalence over the pregnancy episode rather than a population point prevalence, following the convention used on the Preeclampsia entry.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"The HELLP syndrome is a serious complication in pregnancy characterized by haemolysis, elevated liver enzymes and low platelet count occurring in 0.5 to 0.9% of all pregnancies and in 10-20% of cases with severe preeclampsia."

Gives the 0.5-0.9% per-pregnancy occurrence figure asserted in this record.

Pregnancies, general obstetric population (lower published estimate)

Period Prevalence 200.0–800.0 per 100,000 >1 in 1,000

A second review reports a lower and wider band (0.2-0.8% of pregnancies). Both estimates are recorded rather than averaged, because the published range reflects genuinely different diagnostic thresholds (Tennessee vs Mississippi criteria, complete vs partial HELLP) rather than sampling noise.

Show evidence (1 reference)

PMID:23107053 SUPPORT Human Clinical

"HELLP occurs in 0.2-0.8% of pregnancies and in 70-80% of cases it coexists with preeclampsia (PE)."

Provides the alternative 0.2-0.8% occurrence estimate and the proportion coexisting with preeclampsia.

Worldwide (pooled meta-analysis of nine studies, 133,611 participants)

Period Prevalence 390.0 per 100,000 (160.0–720.0) >1 in 1,000

Pooled random-effects estimate of 0.39% (95% CI 0.16-0.72%), i.e. 390 per 100,000 pregnancies. Recorded alongside, not instead of, the two review figures above: the meta-analysis is the most systematic estimate but rests on only nine studies, a limitation its own authors state explicitly, and it sits below both narrative-review bands. The point estimate and the whole confidence interval are nevertheless above 1 in 1,000, so the class matches the two sibling records.

Show evidence (2 references)

PMID:41293035 SUPPORT Human Clinical

"the estimate for HELLP syndrome is 0.39% (95% CI: 0.16%-0.72%), which must be interpreted with considerable caution as it is derived from a limited pool of only nine studies"

Gives the pooled prevalence point estimate and interval, together with the authors' own caveat about the small study pool, which is why this record is added rather than allowed to supersede the review estimates.

PMID:41293035 SUPPORT Human Clinical

"Marked regional disparities were identified, with higher prevalences in low-income countries."

Documents that the pooled figure conceals substantial regional variation.

⚖️

Clinical Burden

High

HELLP is a life-threatening obstetric emergency. It carries substantial maternal and perinatal morbidity and mortality, frequently forces iatrogenic preterm delivery, and in a French nationwide cohort conferred a stronger one-year risk of major adverse cardiovascular events, stroke, thromboembolism, and renal failure than isolated preeclampsia.

Show evidence (2 references)

PMID:15121574 SUPPORT Human Clinical

"The presence of this syndrome is associated with increased risk of adverse outcome for both mother and fetus."

States the adverse maternal and fetal outcome risk that motivates the HIGH burden level.

PMID:42502666 SUPPORT Human Clinical

"PE-HELLP was a significantly stronger risk of major adverse cardiovascular events (MACEs), stroke, thromboembolism, and RF than iPE."

Quantitative population-scale evidence that HELLP carries excess short-term risk beyond isolated preeclampsia.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from HELLP Syndrome:

Acute fatty liver of pregnancy

Overlapping Features The closest mimic. Clinical and biochemical features overlap substantially, and AFLP shares the fetal fatty-acid-oxidation-defect association. The histological discriminator is decisive when tissue is available: HELLP shows periportal coagulation necrosis with no fatty transformation of hepatocytes, whereas AFLP is defined by microvesicular steatosis.

Distinguishing Features

AFLP typically shows hypoglycemia, marked coagulopathy, and hyperammonemia out of proportion to the transaminase rise.
Hypertension and proteinuria are usually absent in AFLP but usually present in HELLP.
Liver histology shows fatty transformation in AFLP and its explicit absence in HELLP.

Show evidence (2 references)

PMID:19245695 SUPPORT Human Clinical

"Clinical signs of AFLP vary and there is significant overlap in clinical and biochemical features"

Establishes the substantial clinical and biochemical overlap that makes AFLP the principal differential.

PMID:11924711 SUPPORT Human Clinical

"lack of fatty transformation of hepatocytes"

The histological feature that separates HELLP from acute fatty liver of pregnancy.

Thrombotic thrombocytopenic purpura Not Yet Curated MONDO:0018896

Overlapping Features Shares microangiopathic hemolysis and thrombocytopenia. TTP is driven by ADAMTS13 deficiency and VWF-platelet aggregation, a mechanistically distinct microangiopathy that does not resolve with delivery and requires plasma exchange.

Distinguishing Features

Prominent neurologic involvement and severe ADAMTS13 deficiency favor TTP.
Failure to improve after delivery argues strongly against HELLP.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"haemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)"

Names TTP among the serious conditions that mimic HELLP and require different therapy.

Hemolytic uremic syndrome

Overlapping Features Also a thrombotic microangiopathy; pregnancy-associated atypical HUS is complement-mediated and may be genuinely difficult to separate from HELLP, especially since a complement arm is proposed for HELLP itself. Persistent renal failure and failure to improve after delivery point to aHUS.

Distinguishing Features

Predominant and persistent renal failure with dialysis requirement favors aHUS.
Persistence or worsening beyond the first postpartum days favors aHUS over HELLP.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"haemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)"

Names HUS among the serious mimics of HELLP requiring a different therapeutic approach.

Immune thrombocytopenic purpura

Overlapping Features A common cause of thrombocytopenia in pregnancy. ITP produces isolated thrombocytopenia without hemolysis or transaminase elevation.

Distinguishing Features

Isolated thrombocytopenia with normal LDH, transaminases, and smear.

Show evidence (1 reference)

PMID:19245695 SUPPORT Human Clinical

"Other less common, but serious conditions that may mimic HELLP, include ITP"

Names ITP among the conditions that may be mistaken for HELLP.

Systemic lupus erythematosus and antiphospholipid syndrome

Overlapping Features Both can produce a pregnancy microangiopathy resembling HELLP, and both are independently associated with HELLP - chronic inflammatory disease and lupus were more strongly associated with HELLP than with isolated preeclampsia in a nationwide cohort. The distinction is therefore often one of co-existence rather than exclusion.

Distinguishing Features

Antiphospholipid antibodies, prior thrombosis, or established lupus point to a coexisting or alternative diagnosis.
Neurologic involvement, dialysis requirement, or absent DIC raise concern for an APS-associated microangiopathy.

Show evidence (1 reference)

PMID:42502666 SUPPORT Human Clinical

"Chronic inflammatory diseases and lupus were more associated with PE-HELLP than iPE."

Population-scale evidence that lupus and chronic inflammatory disease are differentially associated with HELLP.

📊

Related Datasets

1

Genome-wide analysis of placental gene expression in severe preterm preeclampsia geo:GSE66273

human MICROARRAY n=17

PMID:30135684

Selected as a DIRECT candidate by `just discover-datasets HELLP_Syndrome` and manually triaged: the GEO series summary states the placentas came from women with preterm severe preeclampsia "with or without HELLP syndrome", so HELLP cases are genuinely represented rather than the accession merely matching on a disease name. The GENE_ONLY candidates returned by the same search (HADHA-matched cardiomyocyte and murine Treg series) were rejected as Named Entity Confusion - they match the gene symbol cited on this entry's fetal fatty-acid-oxidation arm and have nothing to do with HELLP. Carries no evidence block, per the dataset-curation convention: the accession is verified to exist and be relevant, which is not the same as having an exact quotable finding about HELLP.

🔬

Clinical Trials

2

NCT04103489 PHASE_I COMPLETED

Phase 1 study of eculizumab in early preterm HELLP syndrome (23-30 weeks estimated gestational age), testing whether terminal complement blockade halts or reverses disease progression. This is the registered trial behind the complement arm curated on this entry; its phase-1 design and small enrolment are why C5 blockade is recorded here as investigational rather than as an established treatment.

Target Phenotypes: Thrombocytopenia HP:0001873 Hemolytic anemia HP:0001878

Show evidence (1 reference)

clinicaltrials:NCT04103489 SUPPORT Human Clinical

"This drug blocks a part of the immune system called complement. By blocking this part of the immune system, eculizumab may stop or reverse the progression of the HELLP syndrome disease."

States the trial's complement-blockade rationale, which is the therapeutic hypothesis recorded in the complement discussion on this entry.

NCT01138839 PHASE_III UNKNOWN

Multicentric, double-blind, placebo-controlled randomized trial of dexamethasone in Mississippi class 1 (HELLP I) syndrome. Registered to address exactly the maternal-benefit question the Cochrane review left open; its status is recorded as UNKNOWN because the registry record has not been updated.

Target Phenotypes: Thrombocytopenia HP:0001873

Show evidence (1 reference)

clinicaltrials:NCT01138839 SUPPORT Human Clinical

"The purpose of this study is to determine the efficacy of dexamethasone for treatment of HELLP I (hemolysis, elevated liver enzymes and low platelet count) syndrome."

Confirms that the maternal efficacy of dexamethasone in severe HELLP is a registered, prospectively posed trial question rather than settled.

{ }

Source YAML

click to show

name: HELLP Syndrome
creation_date: "2026-08-18T00:00:00Z"
category: Complex
synonyms:
- Hemolysis, elevated liver enzymes, and low platelet count syndrome
- HELLP
- Hemolysis-elevated liver enzymes-low platelet count syndrome
description: >
  HELLP syndrome is a severe, pregnancy-specific thrombotic microangiopathy defined by
  the laboratory triad of hemolysis, elevated liver enzymes, and a low platelet count.
  It complicates roughly 0.2-1% of pregnancies and coexists with preeclampsia in the
  large majority of cases, arising most often between 27 and 37 weeks of gestation or
  within 48 hours postpartum. HELLP shares its proximal placental pathology with
  preeclampsia - defective trophoblast invasion and spiral artery remodeling, placental
  ischemia, and release of anti-angiogenic factors (sFlt-1, soluble endoglin) that
  injure the maternal endothelium - and this entry deliberately does not re-derive that
  shared upstream chain, which is curated on the Preeclampsia entry. What distinguishes
  HELLP is the downstream microangiopathic arm: a stronger systemic inflammatory and
  prothrombotic response produces platelet-fibrin microthrombi, mechanical erythrocyte
  fragmentation, consumptive thrombocytopenia, and - in the uniquely low-shear hepatic
  sinusoids - sinusoidal obstruction with periportal hepatocyte necrosis. A subset of
  cases carries germline alternative-complement-pathway variants, and a small subset is
  associated with a fetal long-chain fatty-acid oxidation defect. The only definitive
  treatment is delivery of the fetus and placenta.
disease_term:
  preferred_term: HELLP syndrome
  term:
    id: MONDO:0008585
    label: HELLP syndrome
parents:
- Preeclampsia
- Thrombotic microangiopathy
- Hypertensive disorder of pregnancy
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:O14.2
      label: HELLP syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO:0008585
    mapping_justification: >
      MONDO:0008585 carries ICD10CM:O14.2 as a cross-reference, and the French CONCEPTION
      cohort study operationalizes HELLP syndrome case ascertainment using exactly this code.
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: ONCOLOGY_HEMATOLOGY
  - classification_value: GASTROINTESTINAL
clinical_burden:
  burden_level: HIGH
  rationale: >
    HELLP is a life-threatening obstetric emergency. It carries substantial maternal
    and perinatal morbidity and mortality, frequently forces iatrogenic preterm
    delivery, and in a French nationwide cohort conferred a stronger one-year risk of
    major adverse cardiovascular events, stroke, thromboembolism, and renal failure
    than isolated preeclampsia.
  evidence:
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of this syndrome is associated with increased risk of adverse outcome for both mother and fetus."
    explanation: States the adverse maternal and fetal outcome risk that motivates the HIGH burden level.
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PE-HELLP was a significantly stronger risk of major adverse cardiovascular events (MACEs), stroke, thromboembolism, and RF than iPE."
    explanation: Quantitative population-scale evidence that HELLP carries excess short-term risk beyond isolated preeclampsia.
prevalence:
- population: Pregnancies, general obstetric population
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 500.0
  rate_high: 900.0
  notes: >-
    0.5-0.9% of all pregnancies, i.e. 500-900 per 100,000 pregnancies. Modeled as a
    period prevalence over the pregnancy episode rather than a population point
    prevalence, following the convention used on the Preeclampsia entry.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The HELLP syndrome is a serious complication in pregnancy characterized by haemolysis, elevated liver enzymes and low platelet count occurring in 0.5 to 0.9% of all pregnancies and in 10-20% of cases with severe preeclampsia."
    explanation: Gives the 0.5-0.9% per-pregnancy occurrence figure asserted in this record.
- population: Pregnancies, general obstetric population (lower published estimate)
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 200.0
  rate_high: 800.0
  notes: >-
    A second review reports a lower and wider band (0.2-0.8% of pregnancies). Both
    estimates are recorded rather than averaged, because the published range reflects
    genuinely different diagnostic thresholds (Tennessee vs Mississippi criteria,
    complete vs partial HELLP) rather than sampling noise.
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HELLP occurs in 0.2-0.8% of pregnancies and in 70-80% of cases it coexists with preeclampsia (PE)."
    explanation: Provides the alternative 0.2-0.8% occurrence estimate and the proportion coexisting with preeclampsia.
- population: Worldwide (pooled meta-analysis of nine studies, 133,611 participants)
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 390.0
  rate_low: 160.0
  rate_high: 720.0
  notes: >-
    Pooled random-effects estimate of 0.39% (95% CI 0.16-0.72%), i.e. 390 per 100,000
    pregnancies. Recorded alongside, not instead of, the two review figures above: the
    meta-analysis is the most systematic estimate but rests on only nine studies, a
    limitation its own authors state explicitly, and it sits below both narrative-review
    bands. The point estimate and the whole confidence interval are nevertheless above
    1 in 1,000, so the class matches the two sibling records.
  evidence:
  - reference: PMID:41293035
    reference_title: "Global prevalence of preeclampsia, eclampsia, and HELLP syndrome: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the estimate for HELLP syndrome is 0.39% (95% CI: 0.16%-0.72%), which must be interpreted with considerable caution as it is derived from a limited pool of only nine studies"
    explanation: >
      Gives the pooled prevalence point estimate and interval, together with the authors'
      own caveat about the small study pool, which is why this record is added rather
      than allowed to supersede the review estimates.
  - reference: PMID:41293035
    reference_title: "Global prevalence of preeclampsia, eclampsia, and HELLP syndrome: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Marked regional disparities were identified, with higher prevalences in low-income countries."
    explanation: Documents that the pooled figure conceals substantial regional variation.
progression:
- phase: Antepartum onset
  age_range: Usually 27-37 weeks of gestation
  notes: >
    About 70% of cases present before delivery, with a peak between the 27th and 37th
    gestational weeks; onset is usually rapid and the syndrome characteristically
    exacerbates overnight.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 70% of the cases develop before delivery, the majority between the 27th and 37th gestational weeks; the remainder within 48 hours after delivery."
    explanation: Establishes the antepartum timing and its peak gestational window.
- phase: Postpartum onset
  age_range: Within 48 hours of delivery
  notes: >
    The remaining ~30% of cases declare themselves postpartum, typically within 48
    hours, most often in women who already had hypertension and proteinuria before
    delivery. Maternal surveillance is therefore continued for at least 48 hours after
    delivery.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 70% of the cases develop before delivery, the majority between the 27th and 37th gestational weeks; the remainder within 48 hours after delivery."
    explanation: The complement of the antepartum fraction defines the postpartum-onset window.
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Close surveillance of the mother should be continued for at least 48 hours after delivery."
    explanation: Supports the 48-hour postpartum surveillance window implied by this phase.
- phase: Subsequent pregnancies
  age_range: Later pregnancies after an index HELLP pregnancy
  notes: >
    After an index HELLP pregnancy the risk of obstetric complications in later
    pregnancies is high, but the risk of recurrent HELLP specifically is low (3-6%
    across two cohorts). This asymmetry is mechanistically informative: the shared
    placental susceptibility recurs far more readily than the full microangiopathic
    escalation.
  evidence:
  - reference: PMID:7847520
    reference_title: "Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complications included preeclampsia (19%), preterm delivery (21%), intrauterine growth restriction (12%), abruptio placentae (2%), perinatal death (4%), and HELLP syndrome (3%)."
    explanation: Quantifies subsequent-pregnancy complication rates and the 3% HELLP recurrence rate in normotensive women.
  - reference: PMID:12824985
    reference_title: "Subsequent pregnancy outcome in women with a history of HELLP syndrome at < or = 28 weeks of gestation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recurrent hemolysis, elevated liver enzymes, and low platelet count syndrome developed in 4 of these pregnancies (6%)"
    explanation: Confirms a low (6%) HELLP recurrence rate even in the severe early-onset subgroup.
mechanistic_hypotheses:
- hypothesis_group_id: shared_placental_antiangiogenic
  hypothesis_label: Shared Placental Anti-Angiogenic Model with HELLP-Specific Amplification
  status: CANONICAL
  description: >
    HELLP shares its initiating placental lesion with preeclampsia: immune maladaptation
    at the maternal-fetal interface, defective trophoblast invasion, placental ischemia,
    and release of anti-angiogenic factors that injure the maternal endothelium. What is
    HELLP-specific under this model is not a different trigger but a quantitatively
    stronger downstream inflammatory and prothrombotic response, with soluble endoglin
    and Fas ligand rather than sFlt-1 carrying the differential signal, converting
    endothelial dysfunction into frank thrombotic microangiopathy.
  notes: >
    This entry deliberately does not duplicate the full preeclampsia pathograph; the
    shared trigger is represented by a single node and the mechanistic detail of
    trophoblast invasion failure and sFlt-1/VEGF signaling lives on the Preeclampsia
    entry. The evidence below supports amplification, not a distinct upstream cause.
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These factors trigger the vascular endothelium, resulting in an enhanced inflammatory response which is stronger in HELLP."
    explanation: States the core claim of this hypothesis - the same anti-angiogenic factors, a stronger downstream response in HELLP.
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Maternal blood levels of anti-angiogenic sFlt1 are similar, but endoglin and Fas Ligand levels are possibly higher in HELLP than in PE."
    explanation: >
      Supports the claim that the differential signal is carried by endoglin and Fas
      ligand rather than sFlt-1, but is marked PARTIAL because the review itself hedges
      ("possibly higher"), and this entry should not report that hedge as settled.
- hypothesis_group_id: complement_two_hit
  hypothesis_label: Alternative-Complement-Pathway Two-Hit Model
  status: EMERGING
  description: >
    On this model HELLP behaves like an aHUS-type complement-mediated thrombotic
    microangiopathy: a germline defect in alternative-pathway complement regulation
    provides the first hit, and pregnancy provides the second, permitting unrestrained
    terminal complement activation, C5b-9 deposition, and endothelial injury. Its
    strongest support is the enrichment of rare germline alternative-pathway variants
    and positive modified Ham testing in affected women, plus reported clinical response
    to C5 blockade.
  notes: >
    Recorded as EMERGING, not CANONICAL. The genetic evidence is a single case-control
    study (n small, 46% vs 8%), the mHam is a functional surrogate rather than a direct
    measure of in vivo complement-mediated injury, and the eculizumab evidence is case
    reports and small series - there is no randomized trial. The complement arm should
    not be curated as an established causal chain, and this is the reason the C5-blockade
    treatment on this entry is marked as investigational.
  evidence:
  - reference: PMID:29563339
    reference_title: "Germline mutations in the alternative pathway of complement predispose to HELLP syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significantly more participants with rare germline mutations in APC genes were present in the HELLP cohort compared with controls (46% versus 8%, P = 0.01)."
    explanation: The primary genetic observation on which the two-hit model rests.
  - reference: PMID:29563339
    reference_title: "Germline mutations in the alternative pathway of complement predispose to HELLP syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We hypothesize that HELLP syndrome follows a 2-hit disease model similar to atypical hemolytic uremic syndrome (aHUS), requiring both genetic susceptibility and an environmental risk factor."
    explanation: States the two-hit framing directly, and its own wording ("We hypothesize") supports the EMERGING status assigned here.
- hypothesis_group_id: fetal_fao_defect_maternal_liver
  hypothesis_label: Fetal Fatty-Acid-Oxidation-Defect Model (subset of cases)
  status: ALTERNATIVE
  description: >
    In a distinct subset of pregnancies, maternal HELLP or acute fatty liver of pregnancy
    occurs in a heterozygous carrier mother gestating a fetus with a long-chain
    3-hydroxyacyl-CoA dehydrogenase (LCHAD) or mitochondrial trifunctional protein
    deficiency. The proposed mechanism is that 3-hydroxy long-chain acyl intermediates
    accumulating in the deficient fetoplacental unit are exported into the maternal
    circulation and are hepatotoxic to a mother whose own beta-oxidation capacity is
    reduced by heterozygosity and by the metabolic demands of late pregnancy.
  notes: >
    Applies only to a small subset and is genotype-dependent - the association tracked
    the common HADHA Glu474Gln (E474Q) allele and was absent in children with complete
    trifunctional protein deficiency. The metabolite-export mechanism itself is inferred,
    not directly demonstrated in the cited study, which establishes the genetic
    association. The corresponding fatty-acid-oxidation disorder entries
    (Long-Chain_3-Hydroxyacyl-CoA_Dehydrogenase_Deficiency,
    Mitochondrial_Trifunctional_Protein_Deficiency,
    Carnitine_Palmitoyltransferase_1A_Deficiency) already record this relationship from
    the fetal side and were deliberately not modified by this entry.
  evidence:
  - reference: PMID:10352164
    reference_title: "A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome."
    explanation: The quantitative genotype-association result that grounds this alternative model.
  - reference: PMID:10352164
    reference_title: "A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five other children, who presented with neonatal dilated cardiomyopathy or progressive neuromyopathy, had complete deficiency of the trifunctional protein (loss of activity of all three enzymes). None had the Glu474Gln mutation, and none of their mothers had liver disease during pregnancy."
    explanation: >
      Bounds the model: the maternal association is allele-specific and did not extend to
      complete trifunctional protein deficiency, so this is a subset mechanism rather
      than a general one.
pathophysiology:
- name: Placental Ischemia and Anti-Angiogenic Factor Release
  description: >
    The initiating lesion is shared with preeclampsia: immune maladaptation toward the
    invading trophoblast, defective spiral-artery remodeling, and placental malperfusion,
    followed by release of anti-angiogenic factors (sFlt-1, soluble endoglin) together
    with placental necrotic debris and cell-free DNA into the maternal circulation. This
    node is deliberately compressed - the trophoblast-invasion and sFlt-1/VEGF detail is
    curated on the Preeclampsia entry and is not re-derived here. What matters for HELLP
    is that the placental output includes an inflammatory as well as an anti-angiogenic
    component.
  role: trigger
  biological_scale: TISSUE
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  biological_processes:
  - preferred_term: angiogenesis
    term:
      id: GO:0001525
      label: angiogenesis
    modifier: DECREASED
  - preferred_term: vascular endothelial growth factor receptor signaling pathway
    term:
      id: GO:0048010
      label: vascular endothelial growth factor receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunological maladaptation is the most probable trigger of the insult to the invading trophoblast."
    explanation: Establishes the shared upstream trophoblast insult as the probable trigger in HELLP.
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Anti-angiogenic factors released into maternal blood induce the maternal syndromes."
    explanation: Links the placental lesion to release of anti-angiogenic factors as the effector output of this node.
  - reference: PMID:31877439
    reference_title: "The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The placenta releases, besides anti-angiogenetic factors, also necrotic debris and cell-free DNA, a mixture that not only induces systemic endothelial dysfunction as in preeclampsia, but also a systemic inflammatory response."
    explanation: Supports the HELLP-specific addition to this node - a co-released inflammatory component beyond the anti-angiogenic factors.
  downstream:
  - target: Maternal Endothelial Injury and Systemic Inflammatory Amplification
    description: >
      Circulating anti-angiogenic factors plus placental debris injure and activate the
      maternal endothelium and provoke a systemic inflammatory response.
    causal_link_type: DIRECT
    hypothesis_groups:
    - shared_placental_antiangiogenic
    evidence:
    - reference: PMID:31877439
      reference_title: "The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The dysfunctional placenta in women developing HELLP initiates a cascade of events that eventually results in liver dysfunction."
      explanation: Asserts the causal direction from placental dysfunction to the downstream maternal cascade.
- name: Alternative Complement Pathway Dysregulation
  description: >
    In a substantial subset of women, rare germline variants in alternative-pathway
    complement genes reduce complement regulation, and pregnancy acts as the second hit
    permitting unrestrained terminal-pathway activation. Placental C5b-9 deposition is
    increased, and C5b-9 in turn stimulates trophoblast sFlt-1 secretion, so this arm
    both parallels and feeds back onto the anti-angiogenic node above. This node is
    modeled as a parallel, hypothesis-scoped trigger rather than part of the canonical
    chain.
  role: trigger
  biological_scale: MOLECULAR
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  biological_processes:
  - preferred_term: complement activation, alternative pathway
    term:
      id: GO:0006957
      label: "complement activation, alternative pathway"
    modifier: INCREASED
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:29563339
    reference_title: "Germline mutations in the alternative pathway of complement predispose to HELLP syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HELLP syndrome is characterized by both activation of the APC and frequent germline mutations in APC genes."
    explanation: Directly supports both components of this node - functional alternative-pathway activation and germline predisposing variants.
  - reference: PMID:32986992
    reference_title: "Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In women who develop preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, there is a shift toward increased complement activation and decreased complement regulation."
    explanation: Independent review support for loss of complement regulation as a feature of HELLP.
  downstream:
  - target: Placental Ischemia and Anti-Angiogenic Factor Release
    description: >
      Placental C5b-9 deposition stimulates trophoblasts to secrete sFlt-1, feeding the
      anti-angiogenic node; complement dysregulation is therefore upstream of, not merely
      parallel to, the anti-angiogenic output.
    causal_link_type: DIRECT
    hypothesis_groups:
    - complement_two_hit
    evidence:
    - reference: PMID:32986992
      reference_title: "Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "C5b-9 deposition stimulates trophoblasts to secrete soluble fms-like tyrosine kinase-1, which sequesters vascular endothelial growth factor and placental growth factor."
      explanation: Mechanistic link from terminal complement deposition to sFlt-1 release and VEGF/PlGF sequestration.
  - target: Maternal Endothelial Injury and Systemic Inflammatory Amplification
    description: >
      Unrestrained terminal complement activation injures the maternal endothelium
      directly, in the manner of aHUS.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - complement_two_hit
    evidence:
    - reference: PMID:29563339
      reference_title: "Germline mutations in the alternative pathway of complement predispose to HELLP syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Similar to aHUS, treatment via complement inhibition to mitigate maternal and fetal morbidity and mortality may be possible."
      explanation: >
        The authors' framing of HELLP as an aHUS-like complement-mediated microangiopathy
        implies complement-driven endothelial injury; the hedged wording is why this edge
        is scoped to the EMERGING complement hypothesis group.
- name: Fetal Long-Chain Fatty-Acid Oxidation Defect
  description: >
    In a small, genotype-defined subset, the fetus is homozygous or compound
    heterozygous for a long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency
    allele, classically HADHA Glu474Gln, while the mother is an obligate heterozygote.
    Accumulating 3-hydroxy long-chain acyl intermediates in the fetoplacental unit are
    proposed to reach the maternal circulation and injure a maternal liver whose own
    beta-oxidation reserve is reduced. The genetic association is well established; the
    metabolite-transfer step is inferred rather than directly measured.
  role: trigger
  genes:
  - preferred_term: HADHA
    term:
      id: hgnc:4801
      label: HADHA
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:10352164
    reference_title: "A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute fatty liver of pregnancy and the HELLP syndrome (hemolysis, elevated liver-enzyme levels, and a low platelet count) are serious hepatic disorders that may occur during pregnancy in women whose fetuses are later found to have a deficiency of long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase."
    explanation: Establishes the fetal-genotype-to-maternal-liver-disease association that defines this node.
  downstream:
  - target: Periportal Hepatocyte Necrosis and Hepatic Injury
    description: >
      In this subset the maternal hepatic injury tracks the fetal LCHAD genotype rather
      than following from the microangiopathic chain. The edge is scoped to the
      alternative hypothesis group and the intervening metabolite transfer is not
      directly evidenced.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - fetal_fao_defect_maternal_liver
    evidence:
    - reference: PMID:10352164
      reference_title: "A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome."
      explanation: Quantifies the fetal-genotype-conditioned maternal hepatic disease risk that this edge asserts.
- name: Maternal Endothelial Injury and Systemic Inflammatory Amplification
  description: >
    Circulating placental factors activate and injure the maternal vascular endothelium
    and provoke a systemic inflammatory response with activated leukocytes, inflammatory
    cytokines, and active von Willebrand factor. In HELLP this inflammatory amplification
    is stronger than in preeclampsia, and it is the step at which the shared preeclamptic
    endothelial dysfunction is converted into an overtly prothrombotic microvascular
    state.
  role: amplifier
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: blood vessel endothelial cell
    term:
      id: CL:0000071
      label: blood vessel endothelial cell
  biological_processes:
  - preferred_term: endothelial cell activation
    term:
      id: GO:0042118
      label: endothelial cell activation
    modifier: INCREASED
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These factors trigger the vascular endothelium, resulting in an enhanced inflammatory response which is stronger in HELLP."
    explanation: Directly supports endothelial triggering plus the HELLP-specific amplification asserted by this node.
  - reference: PMID:31877439
    reference_title: "The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The latter aggravates the endothelio-toxic effects in the systemic cardiovascular bed, amplifying the already increased pro-thrombotic conditions."
    explanation: Supports the conversion of endothelial injury into a systemic prothrombotic state, the defining output of this node.
  downstream:
  - target: Platelet Activation and Consumptive Thrombocytopenia
    description: >
      Endothelial injury with released active von Willebrand factor drives platelet
      adhesion, activation, and aggregation in the microvasculature.
    causal_link_type: DIRECT
    hypothesis_groups:
    - shared_placental_antiangiogenic
    - complement_two_hit
    evidence:
    - reference: PMID:23107053
      reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "induce thrombotic microangiopathy with platelet-fibrin thrombi in microvessels"
      explanation: Names platelet participation in the microvascular thrombi generated downstream of endothelial and coagulation activation.
  - target: Microangiopathic Erythrocyte Fragmentation and Destruction
    description: >
      Erythrocytes are sheared as they traverse microvessels partly occluded by
      platelet-fibrin thrombi over a damaged endothelial surface.
    causal_link_type: DIRECT
    hypothesis_groups:
    - shared_placental_antiangiogenic
    evidence:
    - reference: PMID:23107053
      reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The angiopathy results in consumption of circulating platelets, causes hemolysis in affected microvessels and reduces portal blood flow in the liver."
      explanation: States that the microangiopathy itself causes hemolysis within affected microvessels.
- name: Platelet Activation and Consumptive Thrombocytopenia
  description: >
    Platelets adhere to and are activated on the injured endothelium and are consumed
    into microvascular platelet-fibrin thrombi. The thrombocytopenia of HELLP is
    therefore consumptive rather than a production failure - which is why platelet nadir
    is used as the severity axis of the Mississippi classification, and why platelet
    transfusion is reserved for bleeding or the most severe class rather than used to
    correct the count.
  role: amplifier
  biological_scale: CELLULAR
  conforms_to: "thrombogenesis#Platelet Adhesion, Activation, and Aggregation"
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: platelet activation
    term:
      id: GO:0030168
      label: platelet activation
    modifier: INCREASED
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The angiopathy results in consumption of circulating platelets, causes hemolysis in affected microvessels and reduces portal blood flow in the liver."
    explanation: Establishes that circulating platelets are consumed by the microangiopathy, the consumptive mechanism this node asserts.
  downstream:
  - target: Hepatic Sinusoidal Microthrombosis and Fibrin Deposition
    description: >
      Activated platelets participate with thrombin-generated fibrin in microthrombi that
      preferentially obstruct the low-shear hepatic sinusoids.
    causal_link_type: DIRECT
    hypothesis_groups:
    - shared_placental_antiangiogenic
    evidence:
    - reference: PMID:31877439
      reference_title: "The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Particularly in microcirculations with extremely low shear forces, such as in the hepatic sinusoids, this will facilitate microthrombi formation and fibrin deposition eventually resulting in obstruction of the sinusoids similar as in SOS."
      explanation: Supports the site-selective step from a systemic prothrombotic state to hepatic sinusoidal microthrombosis.
  - target: Disseminated Intravascular Coagulation and Multiorgan Failure
    description: >
      In roughly half of cases the same coagulation and platelet activation escalates to
      disseminated intravascular coagulation.
    causal_link_type: DIRECT
    hypothesis_groups:
    - shared_placental_antiangiogenic
    evidence:
    - reference: PMID:23107053
      reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In about one half of women with HELLP, activation of coagulation factors and platelets precipitates disseminated intravascular coagulation, which in a minority becomes uncompensated and contributes to life-threatening multiorgan failure."
      explanation: Directly states the escalation from platelet and coagulation-factor activation to DIC.
- name: Microangiopathic Erythrocyte Fragmentation and Destruction
  description: >
    Erythrocytes are mechanically fragmented as they are forced across partly occluded
    microvessels, producing schistocytes on the peripheral smear, intravascular hemolysis
    with raised LDH and indirect bilirubin, and consumed haptoglobin. This is the "H" of
    HELLP and is the extrinsic, mechanical arm of the conserved hemolytic-anemia
    destruction pathway - the erythrocyte itself is normal, the insult is the vessel.
  role: central_effector
  biological_scale: CELLULAR
  conforms_to: "hemolytic_anemia_erythrocyte_destruction#Premature Erythrocyte Destruction"
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The angiopathy results in consumption of circulating platelets, causes hemolysis in affected microvessels and reduces portal blood flow in the liver."
    explanation: >
      Establishes that erythrocyte destruction in HELLP occurs within the affected
      microvessels, i.e. is mechanical and microangiopathic, which is the specialization
      this node makes on the generic hemolytic-anemia destruction node.
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of HELLP syndrome requires the presence of hemolysis based on examination of the peripheral smear, elevated indirect bilirubin levels, or low serum haptoglobin levels"
    explanation: Supports the laboratory signature of intravascular erythrocyte destruction named in this node.
- name: Hepatic Sinusoidal Microthrombosis and Fibrin Deposition
  description: >
    The uniquely low shear of the hepatic sinusoids makes them the preferential site for
    microthrombus formation and fibrin deposition, producing a sinusoidal obstruction
    physiologically analogous to sinusoidal obstruction syndrome, with reduced portal
    inflow and sinusoidal ischemia. This is the hepatic, site-selective step that
    converts a systemic microangiopathy into the liver-dominant clinical picture of
    HELLP.
  role: effector
  biological_scale: TISSUE
  conforms_to: "thrombogenesis#Pathological Fibrin-Platelet Thrombus Formation"
  cell_types:
  - preferred_term: endothelial cell of hepatic sinusoid
    term:
      id: CL:1000398
      label: endothelial cell of hepatic sinusoid
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: blood coagulation, fibrin clot formation
    term:
      id: GO:0072378
      label: "blood coagulation, fibrin clot formation"
    modifier: INCREASED
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
    modifier: INCREASED
  evidence:
  - reference: PMID:31877439
    reference_title: "The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Particularly in microcirculations with extremely low shear forces, such as in the hepatic sinusoids, this will facilitate microthrombi formation and fibrin deposition eventually resulting in obstruction of the sinusoids similar as in SOS."
    explanation: >
      The direct statement of platelet-assisted fibrin thrombus formation at a defined
      vascular site, which is what qualifies this node for branch-level conformance to
      the thrombogenesis module.
  - reference: PMID:11924711
    reference_title: "Maternal death in pregnancy from HELLP syndrome. A report of three medico-legal autopsy cases with special reference to distinctive histopathological alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hepatic haemorrhages sharply demarcated by an extended fibrin network from the surrounding unaffected liver parenchyma"
    explanation: Autopsy confirmation of intrahepatic fibrin deposition in fatal HELLP, i.e. the formed fibrin structure rather than an inferred prothrombotic state.
  downstream:
  - target: Periportal Hepatocyte Necrosis and Hepatic Injury
    description: >
      Sinusoidal obstruction produces ischemic damage and progressive demise of
      hepatocytes.
    causal_link_type: DIRECT
    hypothesis_groups:
    - shared_placental_antiangiogenic
    evidence:
    - reference: PMID:31877439
      reference_title: "The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The latter causes ischemic damage and progressive demise of hepatocytes."
      explanation: Directly states the sinusoidal-obstruction-to-hepatocyte-death step.
- name: Periportal Hepatocyte Necrosis and Hepatic Injury
  description: >
    Hepatocytes die by ischemic (coagulation) necrosis in a characteristically periportal
    distribution, releasing AST and ALT into the maternal circulation - the "EL" of
    HELLP. Two routes converge here: sinusoidal ischemia downstream of microthrombosis,
    and direct hepatocyte death signaling attributed to placental Fas ligand. The
    resulting confluent necrosis and intrahepatic hemorrhage are what underlie hepatic
    capsular distension, subcapsular hematoma, and, rarely, liver rupture.
  role: effector
  biological_scale: TISSUE
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: hepatocyte apoptotic process
    term:
      id: GO:0097284
      label: hepatocyte apoptotic process
    modifier: INCREASED
  - preferred_term: extrinsic apoptotic signaling pathway via death domain receptors
    term:
      id: GO:0008625
      label: extrinsic apoptotic signaling pathway via death domain receptors
    modifier: INCREASED
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Placental Fas Ligand damages hepatocytes, resulting in periportal necrosis."
    explanation: Supports the death-receptor route to periportal hepatocyte necrosis represented by this node.
  - reference: PMID:11924711
    reference_title: "Maternal death in pregnancy from HELLP syndrome. A report of three medico-legal autopsy cases with special reference to distinctive histopathological alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found an almost identical histopathological pattern in the liver (periportal coagulation necrosis"
    explanation: Autopsy evidence that periportal coagulation necrosis is the reproducible hepatic lesion of fatal HELLP.
  downstream:
  - target: Disseminated Intravascular Coagulation and Multiorgan Failure
    description: >
      Progressive hepatic failure contributes to the multiorgan decompensation of severe
      HELLP.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - shared_placental_antiangiogenic
    evidence:
    - reference: PMID:23107053
      reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In about one half of women with HELLP, activation of coagulation factors and platelets precipitates disseminated intravascular coagulation, which in a minority becomes uncompensated and contributes to life-threatening multiorgan failure."
      explanation: >
        Supports the endpoint of multiorgan failure, but is marked PARTIAL because the
        cited sentence attributes DIC to coagulation and platelet activation rather than
        to hepatic necrosis specifically; the hepatic contribution is an indirect route.
- name: Disseminated Intravascular Coagulation and Multiorgan Failure
  description: >
    In about half of women with HELLP, coagulation factor and platelet activation
    precipitates disseminated intravascular coagulation; in a minority this becomes
    uncompensated and drives life-threatening multiorgan failure. This node is the
    organism-scale terminus of the entry.
  role: consequence
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In about one half of women with HELLP, activation of coagulation factors and platelets precipitates disseminated intravascular coagulation, which in a minority becomes uncompensated and contributes to life-threatening multiorgan failure."
    explanation: Establishes both the frequency of DIC and its role in the fatal multiorgan endpoint.
phenotypes:
- category: Hematologic
  name: Microangiopathic hemolytic anemia
  phenotype_term:
    preferred_term: Hemolytic anemia
    term:
      id: HP:0001878
      label: Hemolytic anemia
  frequency: OBLIGATE
  description: >
    Intravascular hemolysis from mechanical erythrocyte fragmentation. Obligate by
    definition - it is the "H" of HELLP, and its absence defines the ELLP variant rather
    than HELLP.
  diagnostic: true
  evidence:
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of HELLP syndrome requires the presence of hemolysis based on examination of the peripheral smear, elevated indirect bilirubin levels, or low serum haptoglobin levels in association with significant elevation in liver enzymes and a platelet count below 100,000/mm(3) after ruling out other causes of hemolysis and thrombocytopenia."
    explanation: >
      Hemolysis is a required diagnostic criterion, which is the basis for the OBLIGATE
      frequency assigned here.
- category: Hematologic
  name: Schistocytes on peripheral blood smear
  phenotype_term:
    preferred_term: Schistocytosis
    term:
      id: HP:0001981
      label: Schistocytosis
  description: >
    Fragmented erythrocytes on the peripheral smear, the morphological signature of
    mechanical microangiopathic hemolysis and one of the accepted ways to establish the
    hemolysis criterion.
  diagnostic: true
  evidence:
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hemolysis based on examination of the peripheral smear"
    explanation: Names peripheral smear examination as a route to documenting the hemolysis criterion.
- category: Hematologic
  name: Thrombocytopenia
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  frequency: OBLIGATE
  description: >
    Platelet count below 100 x 10^9/L, consumptive in mechanism. The platelet nadir is
    the axis on which the Mississippi triple-class system grades severity.
  diagnostic: true
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
    explanation: >
      The platelet threshold is a required diagnostic criterion, supporting the OBLIGATE
      frequency.
- category: Hepatic
  name: Elevated serum aspartate aminotransferase
  phenotype_term:
    preferred_term: Elevated circulating aspartate aminotransferase concentration
    term:
      id: HP:0031956
      label: Elevated circulating aspartate aminotransferase concentration
  frequency: OBLIGATE
  description: >
    AST at or above 70 IU/L in the Tennessee criteria, released by necrotic periportal
    hepatocytes. The "EL" of HELLP.
  diagnostic: true
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
    explanation: AST elevation is a required diagnostic criterion, supporting the OBLIGATE frequency.
- category: Hepatic
  name: Elevated serum alanine aminotransferase
  phenotype_term:
    preferred_term: Elevated circulating alanine aminotransferase concentration
    term:
      id: HP:0031964
      label: Elevated circulating alanine aminotransferase concentration
  description: >
    ALT is accepted interchangeably with AST in the Mississippi classification and is
    part of the same hepatocellular-injury signature.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in addition to the specific PLT count"
    explanation: >
      The Mississippi criteria admit AST or ALT interchangeably at the same threshold,
      supporting ALT elevation as a recognized manifestation.
- category: Hepatic
  name: Hepatic subcapsular hematoma and liver rupture
  phenotype_term:
    preferred_term: Hepatic subcapsular hematoma and liver rupture
    term:
      id: HP:6000998
      label: Liver rupture
  frequency: VERY_RARE
  description: >
    Confluent periportal necrosis and intrahepatic hemorrhage distend the liver capsule
    and can dissect beneath it as a subcapsular hematoma, which occasionally ruptures into
    the peritoneum. Uncommon but the signature catastrophic complication of HELLP:
    subcapsular hematoma is reported between 0.9% and under 2% of cases, and rupture at
    about 1.8%.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subcapsular liver hematoma Between  0.9% and <2%"
    explanation: >
      The review's complication table reports subcapsular liver hematoma between 0.9% and
      under 2% of HELLP cases, which maps to the VERY_RARE (1-4%) band. The double space
      after "Between" is present in the cached source.
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver rupture >200 cases or about 1.8%"
    explanation: >
      The same table reports frank liver rupture at about 1.8%, also within the VERY_RARE
      band.
  notes: >
    Hematoma and rupture are recorded as one phenotype rather than split, because the HPO
    term used here defines liver rupture explicitly in terms of subcapsular hematoma
    formation ("characterized by the development of a hematoma, often quite large, beneath
    the liver capsule"). The `preferred_term` names both so the entry does not read as
    covering only the rupture endpoint.
- category: Hematologic
  name: Elevated lactate dehydrogenase
  phenotype_term:
    preferred_term: Increased circulating lactate dehydrogenase concentration
    term:
      id: HP:0025435
      label: Increased circulating lactate dehydrogenase concentration
  frequency: OBLIGATE
  description: >
    LDH above 600 U/L, reflecting both erythrocyte lysis and hepatocellular necrosis.
    Required in both the Tennessee and Mississippi criteria.
  diagnostic: true
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
    explanation: >
      Names LDH above 600 U/L as one of the three required Tennessee criteria, which is
      the direct support for the OBLIGATE frequency band.
- category: Hematologic
  name: Reduced haptoglobin
  phenotype_term:
    preferred_term: Reduced haptoglobin level
    term:
      id: HP:0020181
      label: Reduced haptoglobin level
  description: >
    Haptoglobin is consumed binding free hemoglobin released by intravascular hemolysis,
    and a low level is one of the accepted routes to documenting the hemolysis criterion.
  evidence:
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "or low serum haptoglobin levels in association with significant elevation in liver enzymes"
    explanation: Names low serum haptoglobin as an accepted marker of the hemolysis required for diagnosis.
- category: Hematologic
  name: Hyperbilirubinemia
  phenotype_term:
    preferred_term: Hyperbilirubinemia
    term:
      id: HP:0002904
      label: Hyperbilirubinemia
  description: >
    Predominantly indirect (unconjugated) hyperbilirubinemia from hemoglobin catabolism
    after intravascular hemolysis.
  evidence:
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of HELLP syndrome requires the presence of hemolysis based on examination of the peripheral smear, elevated indirect bilirubin levels, or low serum haptoglobin levels"
    explanation: Names elevated indirect bilirubin as an accepted marker of the hemolysis criterion.
- category: Gastrointestinal
  name: Right upper quadrant or epigastric pain
  phenotype_term:
    preferred_term: Epigastric pain
    term:
      id: HP:0410019
      label: Epigastric pain
  frequency: VERY_FREQUENT
  description: >
    Typically the presenting symptom, attributed to hepatic capsular distension by
    intrahepatic swelling, necrosis, and hemorrhage. May fluctuate in a colic-like
    pattern.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typical clinical symptoms are right upper abdominal quadrant or epigastric pain, nausea and vomiting."
    explanation: >
      Names right upper quadrant/epigastric pain first among the typical clinical symptoms
      of HELLP. "Typical" maps to VERY_FREQUENT under Pattern C (qualitative-term mapping)
      of docs/frequency-evidence-guidelines.md.
- category: Gastrointestinal
  name: Nausea and vomiting
  phenotype_term:
    preferred_term: Nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
  frequency: VERY_FREQUENT
  description: Common accompanying symptom, often mistaken for a nonspecific viral illness.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typical clinical symptoms are right upper abdominal quadrant or epigastric pain, nausea and vomiting."
    explanation: >
      Names nausea and vomiting among the same list of typical clinical symptoms.
      "Typical" maps to VERY_FREQUENT under Pattern C of
      docs/frequency-evidence-guidelines.md; because this band rests on the identical
      sentence as the epigastric-pain band, the two are held equal rather than split on
      an unevidenced distinction.
- category: Neurologic
  name: Headache
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  frequency: FREQUENT
  description: Reported by up to 30-60% of affected women.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Up to 30–60% of women have headache"
    explanation: >
      Gives the 30-60% headache figure that maps to the FREQUENT (30-79%) band. The
      cached source is a hard-wrapped PDF extraction and the clause continues onto the
      next physical line as "have headache; about 20% visual symptoms", so the sentence
      cannot be quoted whole; the quoted fragment is the half that carries the number
      this band rests on.
- category: Cardiovascular
  name: Hypertension
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  frequency: FREQUENT
  description: >
    Present in the majority but explicitly not required - hypertension and proteinuria
    are absent in 10-20% of cases, which is precisely why HELLP is missed when clinicians
    anchor on blood pressure.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypertension and proteinuria, which may be absent in 10–20% of the cases"
    explanation: >
      The review states the majority have hypertension and proteinuria but that these may
      be absent in 10-20% of cases, supporting a FREQUENT rather than OBLIGATE band.
  - reference: PMID:7055180
    reference_title: "Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This entity has been termed the HELLP syndrome and may occur when the usual clinical findings to diagnose severe preeclampsia are absent."
    explanation: The original description already recorded that the usual preeclampsia findings may be absent.
- category: Renal
  name: Proteinuria
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
  frequency: FREQUENT
  description: Usually present alongside hypertension, but absent in 10-20% of cases.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypertension and proteinuria, which may be absent in 10–20% of the cases"
    explanation: Same source and reasoning as for hypertension; supports FREQUENT rather than OBLIGATE.
- category: Hematologic
  name: Disseminated intravascular coagulation
  phenotype_term:
    preferred_term: Disseminated intravascular coagulation
    term:
      id: HP:0005521
      label: Disseminated intravascular coagulation
  frequency: FREQUENT
  description: >
    Develops in about half of affected women; uncompensated DIC in a minority drives
    life-threatening multiorgan failure.
  evidence:
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In about one half of women with HELLP, activation of coagulation factors and platelets precipitates disseminated intravascular coagulation"
    explanation: >
      "About one half" maps to the FREQUENT (30-79%) band and is a direct quantitative
      statement, satisfying the frequency-evidence requirement.
- category: Renal
  name: Acute kidney injury
  phenotype_term:
    preferred_term: Acute kidney injury
    term:
      id: HP:0001919
      label: Acute kidney injury
  description: >
    HELLP carries a higher burden of renal involvement than isolated preeclampsia, and
    the excess renal-failure risk persists beyond the first postpartum year.
  evidence:
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HELLP syndrome is associated with a higher burden of multiorgan involvement, including acute kidney injury and severe hematological and hepatic conditions."
    explanation: Directly associates HELLP with acute kidney injury as part of its multiorgan burden.
- category: Neurologic
  name: Eclamptic seizures
  phenotype_term:
    preferred_term: Eclamptic seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  description: >
    Eclampsia complicated 6.5% of PE-HELLP pregnancies in a nationwide French cohort,
    which is why magnesium sulfate seizure prophylaxis is standard even when blood
    pressure is not markedly raised.
  evidence:
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among women who had PE-HELLP, 10.5% had gestational diabetes, 45.1% had an early PE, 6.5% had an eclampsia"
    explanation: >
      A directly reported eclampsia rate of 6.5% among women with PE-HELLP in a
      2.8-million-pregnancy cohort, which sits in the OCCASIONAL (5-29%) band.
  notes: >
    An earlier revision took this band from the 4-9% row of Table 3 in PMID:19245695. That
    row agrees but is a table cell too short to quote as evidence, and padding it out with
    the table's header row would satisfy the word counter while leaving exactly the
    unverifiable-table-cell citation that guard exists to prevent. The cohort figure is
    quoted instead; it is also a single population rather than a pooled range, so no
    band-straddle caveat is needed.
- category: Obstetric
  name: Placental abruption
  phenotype_term:
    preferred_term: Placental abruption
    term:
      id: HP:0011419
      label: Placental abruption
  description: >
    Reported in 9-20% of HELLP pregnancies and a major contributor to postpartum
    hemorrhage and perinatal death.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe ascites, abruptio placentae, oliguria, pulmonary oedema or eclampsia"
    explanation: >
      Names abruptio placentae among the severe maternal complications of HELLP that are
      indications for immediate delivery.
  notes: >
    No frequency band is asserted. Table 3 of the same review reports abruptio placentae
    at 9-20%, which would be OCCASIONAL, but that table row cannot be quoted as evidence:
    it is under the five-word minimum for an evidence snippet, and the rows cannot be
    joined because the trailing citation bracket is stripped from the snippet but not from
    the cached text. Per CLAUDE.md the band is omitted rather than hung on a quote that
    does not state it; the figure is retained in the description.
- category: Respiratory
  name: Pulmonary edema
  phenotype_term:
    preferred_term: Pulmonary edema
    term:
      id: HP:0100598
      label: Pulmonary edema
  description: >
    Reported in 3-10% of HELLP pregnancies, reflecting endothelial permeability and
    volume shifts in severe disease.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe ascites, abruptio placentae, oliguria, pulmonary oedema or eclampsia"
    explanation: >
      Names pulmonary oedema among the severe maternal complications of HELLP that are
      indications for immediate delivery.
  notes: >
    No frequency band is asserted, for the same reason recorded on placental abruption:
    Table 3 reports pulmonary oedema at 3-10% but that row is under the five-word evidence
    minimum and cannot be joined to its neighbours. The figure is kept in the description.
- category: Gastrointestinal
  name: Ascites
  phenotype_term:
    preferred_term: Ascites
    term:
      id: HP:0001541
      label: Ascites
  description: Severe ascites is reported in 4-11% of HELLP pregnancies.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe ascites, abruptio placentae, oliguria, pulmonary oedema or eclampsia"
    explanation: >
      Names severe ascites among the severe maternal complications of HELLP that are
      indications for immediate delivery.
  notes: >
    No frequency band is asserted, for the same reason recorded on placental abruption:
    Table 3 reports severe ascites at 4-11% but that row is under the five-word evidence
    minimum and cannot be joined to its neighbours. Had it been quotable the band would be
    OCCASIONAL - the published range straddles the VERY_RARE/OCCASIONAL boundary at 5%,
    and both the midpoint (7.5%) and most of the interval sit above it. Revisit if a
    single-cohort figure in prose becomes available.
- category: Obstetric
  name: Preterm birth
  phenotype_term:
    preferred_term: Premature birth
    term:
      id: HP:0001622
      label: Premature birth
  frequency: FREQUENT
  description: >
    Reported in 70% of HELLP pregnancies, 15% of them before 28 weeks. Largely
    iatrogenic: delivery is the only definitive treatment, so a diagnosis remote from
    term forces preterm delivery.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Preterm delivery4 70 (15% < 28 gestational weeks)"
    explanation: >
      A directly reported preterm-delivery rate of 70% (the trailing "4" is the source
      table's footnote marker), which maps to the FREQUENT (30-79%) band. This replaces
      an earlier inference from onset timing, which stated when HELLP begins rather than
      how often delivery is preterm.
- category: Obstetric
  name: Fetal growth restriction
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  frequency: FREQUENT
  description: >
    Reported in 38-61% of HELLP pregnancies in a review's pooled complication table, and
    51.2% of PE-HELLP infants were small for gestational age in a 2.8-million-pregnancy
    French cohort. Reflects the same underlying placental insufficiency, and commonly
    co-occurs with HELLP in high-risk cohorts.
  evidence:
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After PE-HELLP, 51.2% of children were small for gestational age, 64.5% were preterm, and 0.4% died in utero or after birth."
    explanation: >
      A directly reported small-for-gestational-age rate of 51.2% after PE-HELLP in a
      nationwide French cohort, which maps to the FREQUENT (30-79%) band. Preferred over
      the review's 38-61% complication-table row, which agrees but is a table cell too
      short to quote as evidence.
  - reference: PMID:35475405
    reference_title: "Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some outcomes overlapped because FGR commonly complicated PE and HELLP syndrome."
    explanation: Documents frequent co-occurrence of fetal growth restriction with HELLP in a high-risk cohort.
histopathology:
- name: Periportal hepatic coagulation necrosis
  finding_term:
    preferred_term: Periportal hepatic coagulative necrosis
    term:
      id: NCIT:C39608
      label: Coagulative Necrosis
  description: >
    Coagulative necrosis in a periportal distribution, with intrahepatic hemorrhages
    demarcated by an extended fibrin network, focal sinusoidal leukostasis, and Kupffer
    cell swelling. Notably there is no inflammatory infiltrate in the liver plates and no
    fatty change - the latter is the key histological discriminator from acute fatty
    liver of pregnancy.
  diagnostic: true
  evidence:
  - reference: PMID:11924711
    reference_title: "Maternal death in pregnancy from HELLP syndrome. A report of three medico-legal autopsy cases with special reference to distinctive histopathological alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found an almost identical histopathological pattern in the liver (periportal coagulation necrosis, hepatic haemorrhages sharply demarcated by an extended fibrin network from the surrounding unaffected liver parenchyma, focal leukostasis in liver sinusoids and swelling of Kupffer's cells, absence of inflammatory cellular infiltrates in liver plates, lack of fatty transformation of hepatocytes)"
    explanation: >
      Full description of the reproducible hepatic lesion across three fatal cases,
      including the absence of fatty change that separates HELLP from acute fatty liver
      of pregnancy.
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Placental Fas Ligand damages hepatocytes, resulting in periportal necrosis."
    explanation: Independent statement that periportal necrosis is the characteristic hepatic lesion of HELLP.
- name: Glomerular endothelial swelling with bloodless glomeruli
  description: >
    The renal lesion in fatal HELLP: bloodless glomeruli with swollen, vacuolated
    intracapillary cells, cigar-shaped capillary loops, enlarged tufts herniating into the
    proximal convoluted tubule, and mesangial cell swelling. This is a renal thrombotic
    microangiopathy pattern rather than an inflammatory glomerulonephritis.
  notes: >
    Deliberately left without a `finding_term`. The composite lesion quoted here has no
    adequate counterpart in the available pathology vocabularies - the nearest candidates
    name either a generic thrombotic microangiopathy or a single component (endothelial
    swelling) and would drop the bloodless-glomerulus and capillary-loop-herniation
    features that make the description diagnostic. No term beats a bad one; this absence
    is a curation decision, not an oversight.
  evidence:
  - reference: PMID:11924711
    reference_title: "Maternal death in pregnancy from HELLP syndrome. A report of three medico-legal autopsy cases with special reference to distinctive histopathological alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "kidneys (bloodless glomeruli with swollen and vacuolated intracapillary cells, cigar-shaped capillary loops, enlarged glomerular tufts with herniation of capillary loops into the proximal convoluted tubules, swelling of mesangial cells)"
    explanation: Describes the reproducible renal histopathology observed in fatal HELLP.
biochemical:
- name: Serum lactate dehydrogenase
  notes: >
    Elevated above 600 U/L in both the Tennessee and Mississippi criteria. LDH is
    released by both lysed erythrocytes and necrotic hepatocytes, so it indexes two of
    the three components of the triad at once and is not specific to either.
  presence: INCREASED
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
    explanation: Gives the diagnostic LDH threshold used in this record.
- name: Serum aspartate aminotransferase
  notes: AST at or above 70 IU/L in both classification systems.
  presence: INCREASED
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
    explanation: Gives the diagnostic AST threshold used in this record.
- name: Platelet count
  notes: >
    Below 100 x 10^9/L for diagnosis; the nadir at any point in the illness grades
    Mississippi class (class 1 at or below 50, class 2 between 50 and 100, class 3 between
    100 and 150).
  presence: DECREASED
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts."
    explanation: Supports the use of platelet nadir as the severity axis described here.
- name: Serum haptoglobin
  notes: Consumed by free hemoglobin; a low level documents intravascular hemolysis.
  presence: DECREASED
  evidence:
  - reference: PMID:15121574
    reference_title: "Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "or low serum haptoglobin levels in association with significant elevation in liver enzymes"
    explanation: Names low haptoglobin as an accepted marker of the required hemolysis.
- name: Soluble endoglin
  notes: >
    An anti-angiogenic placental factor. Circulating levels are raised in HELLP and
    perform comparably to the sFlt-1/PlGF ratio for detection, and one review suggests
    endoglin - unlike sFlt-1 - may run higher in HELLP than in preeclampsia. That
    HELLP-versus-preeclampsia differential is reported with hedging and is treated here
    as suggestive rather than established.
  presence: INCREASED
  evidence:
  - reference: PMID:35475405
    reference_title: "Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Higher levels were observed in HELLP syndrome and EOPE cases."
    explanation: Direct observation of raised sFlt-1/PlGF and soluble endoglin in HELLP cases.
  - reference: PMID:35475405
    reference_title: "Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "0.895 (95%-Cl 0.83-0.96) and 0.878 (95%-Cl 0.81-0.95) in HELLP syndrome"
    explanation: Quantifies detection performance of the sFlt-1/PlGF ratio and soluble endoglin for HELLP.
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Maternal blood levels of anti-angiogenic sFlt1 are similar, but endoglin and Fas Ligand levels are possibly higher in HELLP than in PE."
    explanation: >
      Supports the HELLP-versus-preeclampsia differential for endoglin, but is marked
      PARTIAL because the source itself hedges with "possibly".
genetic:
- name: Alternative complement pathway genes
  notes: >
    Rare germline variants in alternative-pathway complement genes are enriched in women
    with HELLP relative to healthy pregnant controls (46% vs 8%), consistent with a
    susceptibility rather than a Mendelian causal role. HELLP is not a monogenic disorder;
    no single genetic cause has been identified.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:29563339
    reference_title: "Germline mutations in the alternative pathway of complement predispose to HELLP syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significantly more participants with rare germline mutations in APC genes were present in the HELLP cohort compared with controls (46% versus 8%, P = 0.01)."
    explanation: The case-control enrichment that grounds a SUSCEPTIBILITY rather than causal classification.
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No single world-wide genetic cause for excessive risk of HELLP or PE has been identified."
    explanation: Explicitly rules out a monogenic architecture, supporting the polygenic/susceptibility framing.
- name: HADHA (fetal genotype)
  gene_term:
    preferred_term: HADHA
    term:
      id: hgnc:4801
      label: HADHA
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:10352164
    reference_title: "A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome."
    explanation: The fetal-genotype-conditioned maternal risk that defines this entry.
  notes: >
    A distinctive genetic association in which the relevant genotype is the FETUS's, not
    the mother's: maternal HELLP or acute fatty liver of pregnancy is strongly associated
    with gestating a fetus homozygous or compound heterozygous for the HADHA Glu474Gln
    LCHAD-deficiency allele, the mother being an obligate heterozygote. Recorded here as
    a modifier of maternal risk rather than as a cause of HELLP in general.

    Curated only as a cross-reference from the maternal side. The corresponding fetal
    disorders are curated separately in
    Long-Chain_3-Hydroxyacyl-CoA_Dehydrogenase_Deficiency,
    Mitochondrial_Trifunctional_Protein_Deficiency, and
    Carnitine_Palmitoyltransferase_1A_Deficiency, none of which were modified by this
    entry.
definitions:
- name: Tennessee Classification System for HELLP syndrome
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >
    Sibai's strict laboratory criteria for "true" or "complete" HELLP syndrome. All three
    components must be present; cases meeting only one or two are termed partial or
    incomplete HELLP (and, where hemolysis is absent, ELLP).
  scope: >
    Diagnostic case definition for complete HELLP syndrome; the more widely used of the
    two systems for establishing whether a case is HELLP at all.
  criteria_sets:
  - name: Tennessee complete-HELLP criteria
    description: >
      All three laboratory criteria required for complete HELLP syndrome.
    inclusion_criteria:
    - preferred_term: Hemolysis
      description: >
        Intravascular hemolysis, evidenced by an abnormal peripheral blood smear, raised
        serum bilirubin (>= 20.5 micromol/L or >= 1.2 mg/100 mL), and LDH > 600 U/L.
    - preferred_term: Elevated liver enzymes
      description: AST >= 70 IU/L.
    - preferred_term: Low platelet count
      description: Platelets <= 100 x 10^9/L.
    evidence:
    - reference: PMID:19245695
      reference_title: "The HELLP syndrome: clinical issues and management. A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
      explanation: Source for all three thresholds transcribed into this criteria set.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Tennessee Classification System diagnostic criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (>or= 70 U/L), and platelets < 100 x 10(9)/L."
    explanation: States the three Tennessee thresholds transcribed into this criteria set.
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intravascular haemolysis is diagnosed by abnormal peripheral blood smear, increased serum bilirubin"
    explanation: Specifies how the hemolysis component of the Tennessee criteria is established.
  notes: >
    The published Tennessee platelet criterion is written as "< 100" in the review's prose
    and "<= 100" in its Table 1; the criteria set records the table form. This is a real
    inconsistency in the source, not a transcription error.
- name: Mississippi Triple-Class HELLP System
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >
    Martin's severity grading, which stratifies HELLP by the platelet nadir reached at any
    point in the illness rather than by presenting values. Class 1 and 2 additionally
    require LDH > 600 U/L and AST or ALT >= 70 IU/L; class 3 relaxes the transaminase
    threshold to >= 40 IU/L and is regarded as a clinically significant transition phase
    capable of progressing. Unlike the Tennessee system this is a severity axis, not an
    inclusion test - the two answer different questions and should not be conflated.
  scope: >
    Severity classification of established HELLP syndrome, used to guide the intensity of
    surveillance and intervention.
  criteria_sets:
  - name: Mississippi class 1 (severe)
    description: Platelet nadir <= 50 x 10^9/L, with AST or ALT >= 70 IU/L and LDH >= 600 IU/L.
    evidence:
    - reference: PMID:19245695
      reference_title: "The HELLP syndrome: clinical issues and management. A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts."
      explanation: Source for grading Mississippi class on the platelet nadir.
  - name: Mississippi class 2 (moderate)
    description: Platelet nadir > 50 and <= 100 x 10^9/L, with AST or ALT >= 70 IU/L and LDH >= 600 IU/L.
    evidence:
    - reference: PMID:19245695
      reference_title: "The HELLP syndrome: clinical issues and management. A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Class 1 and class 2 are associated with haemolysis (LDH > 600 U/L) and elevated AST ( ≥ 70 U/L) concentration"
      explanation: >-
        Source for the shared class 1 and class 2 haemolysis and transaminase
        requirements; the class boundary itself is the platelet nadir.
  - name: Mississippi class 3 (mild / transition phase)
    description: >
      Platelet nadir > 100 and <= 150 x 10^9/L, with LDH > 600 U/L and AST >= 40 IU/L.
      Considered a transition stage capable of progression rather than a benign category.
    evidence:
    - reference: PMID:19245695
      reference_title: "The HELLP syndrome: clinical issues and management. A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in addition to the specific PLT count"
      explanation: Source for the relaxed class-3 transaminase threshold recorded here.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Mississippi Triple-class HELLP System further classifies the disorder by the nadir platelet counts."
    explanation: Establishes that the Mississippi system grades severity on the platelet nadir.
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in addition to the specific PLT count"
    explanation: Supports the relaxed class-3 transaminase threshold recorded in this criteria set.
  notes: >
    Because the two systems use different platelet thresholds and different transaminase
    cut-offs, published HELLP series are not directly comparable unless the classification
    used is stated - a point the source review makes explicitly about the difficulty of
    comparing the literature.
treatments:
- name: Delivery of the fetus and placenta
  description: >
    The only definitive treatment. Removing the placenta removes the source of the
    anti-angiogenic and inflammatory drive, and the syndrome resolves. Delivery is
    indicated once the 34th gestational week is reached, or at any gestation if maternal
    or fetal condition deteriorates; before 34 weeks a short expectant interval may be
    taken to complete fetal lung maturation.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Induction of Labor
    term:
      id: NCIT:C92814
      label: Induction of Labor
  target_mechanisms:
  - target: Placental Ischemia and Anti-Angiogenic Factor Release
    treatment_effect: INHIBITS
    description: >
      Delivery of the placenta physically removes the organ generating the
      anti-angiogenic and inflammatory output that drives the entire cascade.
    evidence:
    - reference: PMID:19245695
      reference_title: "The HELLP syndrome: clinical issues and management. A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Delivery is indicated if the HELLP syndrome occurs after the 34th gestational week or the foetal and/or maternal conditions deteriorate."
      explanation: Establishes delivery as the intervention of record and states its timing indication.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vaginal delivery is preferable. If the cervix is unfavourable, it is reasonable to induce cervical ripening and then labour."
    explanation: Supports induction of labour with vaginal delivery as the preferred route.
- name: Cesarean delivery
  description: >
    Used when vaginal delivery is not feasible or maternal or fetal deterioration demands
    immediate delivery. Recorded separately from induction because the two are different
    procedures with different risk profiles in a thrombocytopenic patient.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Cesarean Section
    term:
      id: NCIT:C46088
      label: Cesarean Section
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vaginal delivery is preferable. If the cervix is unfavourable, it is reasonable to induce cervical ripening and then labour."
    explanation: >
      Supports cesarean as the non-preferred alternative route. Marked PARTIAL because the
      quoted guidance states the preference for vaginal delivery rather than the
      indications for cesarean.
- name: Antenatal corticosteroid therapy
  description: >
    Betamethasone or dexamethasone, given between 24 and 34 weeks primarily for fetal lung
    maturation. Its value for the maternal syndrome is a genuine controversy and this
    entry does not resolve it: a Cochrane review of 11 trials found improved platelet
    counts (dexamethasone more than betamethasone) but no clear effect on maternal death,
    severe maternal morbidity, or perinatal death, and concluded there is insufficient
    evidence for routine use.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dexamethasone
      term:
        id: CHEBI:41879
        label: dexamethasone
    - preferred_term: betamethasone
      term:
        id: CHEBI:3077
        label: betamethasone
  target_phenotypes:
  - preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:20824872
    reference_title: "Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The only clear effect of treatment on individual outcomes was improved platelet count (standardized mean difference (SMD) 0.67, 95% CI 0.24 to 1.10)."
    explanation: >
      Quantifies the one demonstrated maternal effect - a platelet-count improvement -
      and, by naming it as the only clear effect, is PARTIAL support for corticosteroids
      as a treatment of the maternal syndrome.
  - reference: PMID:20824872
    reference_title: "Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "There is to date insufficient evidence of benefits in terms of substantive clinical outcomes to support the routine use of steroids for the management of HELLP."
    explanation: >
      Refutes routine corticosteroid use for the maternal syndrome. Retained deliberately
      alongside the supporting item so the entry records the controversy rather than
      picking a side.
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Standard corticosteroid treatment is, however, of uncertain clinical value in the maternal HELLP syndrome."
    explanation: Independent review agreement that the maternal benefit is uncertain, while fetal lung maturation remains the accepted indication.
  notes: >
    The fetal-lung-maturation indication (a single course between 24 and 34 weeks) is not
    in dispute; what the Cochrane review questions is corticosteroid treatment of the
    maternal syndrome itself. High-dose and repeated courses should be avoided.
- name: Magnesium sulfate seizure prophylaxis
  description: >
    Given to prevent eclamptic seizures, which complicate 4-9% of HELLP pregnancies.
    Prophylaxis is standard in HELLP even when hypertension is mild or absent, because
    seizure risk does not track blood pressure in this syndrome.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Anticonvulsant Therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
    therapeutic_agent:
    - preferred_term: magnesium sulfate
      term:
        id: CHEBI:32599
        label: magnesium sulfate
  target_phenotypes:
  - preferred_term: Eclamptic seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among women who had PE-HELLP, 10.5% had gestational diabetes, 45.1% had an early PE, 6.5% had an eclampsia"
    explanation: >
      Quantifies the eclampsia risk that seizure prophylaxis addresses: 6.5% of women with
      PE-HELLP had an eclampsia in a nationwide cohort.
  notes: >
    The magnitude of magnesium sulfate's benefit is established in severe preeclampsia
    broadly rather than in HELLP-specific randomized trials; no HELLP-restricted trial
    evidence is cited here, and none should be implied.
- name: Antihypertensive therapy
  description: >
    Blood pressure control targeting below 155/105 mmHg, to reduce the risk of maternal
    stroke and abruption while the definitive intervention is arranged.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Antihypertensive Therapy
    term:
      id: NCIT:C172184
      label: Antihypertensive Therapy
  target_phenotypes:
  - preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood pressure should be kept below 155/105 mmHg."
    explanation: States the blood-pressure target this treatment implements.
- name: Platelet transfusion
  description: >
    Reserved for active bleeding or the most severe (Mississippi class 1) disease around
    delivery. Because the thrombocytopenia is consumptive, transfusion corrects the count
    only transiently and is not used to normalize a number.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: Platelet Transfusion
    term:
      id: NCIT:C15366
      label: Platelet Transfusion
  target_phenotypes:
  - preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a recent study of women with class 1 HELLP syndrome adding of platelet transfusion to standard CS administration did not increase the recovery rate"
    explanation: >
      The review discusses platelet transfusion specifically in the context of class 1
      HELLP, supporting the restricted indication recorded here.
- name: Terminal complement (C5) blockade with eculizumab
  description: >
    INVESTIGATIONAL. A monoclonal antibody against complement C5, used off-label in
    reported cases of severe early preeclampsia/HELLP on the rationale that HELLP is an
    aHUS-like complement-mediated microangiopathy. In one reported case at 26 weeks it
    produced marked clinical improvement, normalized laboratory parameters, and prolonged
    pregnancy by 17 days. There is no randomized trial evidence, and this entry records
    it as an open question rather than as standard care.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: eculizumab
      term:
        id: NCIT:C48386
        label: Eculizumab
  target_mechanisms:
  - target: Alternative Complement Pathway Dysregulation
    treatment_effect: INHIBITS
    description: >
      Blockade of C5 prevents formation of the terminal C5b-9 complex, the effector of the
      complement arm modeled by this node.
    evidence:
    - reference: PMID:32986992
      reference_title: "Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These findings suggest that the inhibition of the terminal complement pathway, possibly through C5 blockade, may be an effective strategy to treat preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, but this strategy warrants further evaluation in clinical trials."
      explanation: >
        Supports the mechanistic rationale for C5 blockade while explicitly stating that
        clinical-trial evaluation is still required, which is why this link is PARTIAL.
  evidence:
  - reference: PMID:23228435
    reference_title: "Eculizumab for the treatment of preeclampsia/HELLP syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters."
    explanation: >
      A single-patient report of clinical and laboratory response. Marked PARTIAL because
      an uncontrolled n-of-1 observation in a self-limiting-on-delivery condition cannot
      establish efficacy.
  notes: >
    Deliberately not curated as an established treatment. See the KNOWLEDGE_GAP discussion
    on the complement arm.
differential_diagnoses:
- name: Acute fatty liver of pregnancy
  description: >
    The closest mimic. Clinical and biochemical features overlap substantially, and AFLP
    shares the fetal fatty-acid-oxidation-defect association. The histological
    discriminator is decisive when tissue is available: HELLP shows periportal coagulation
    necrosis with no fatty transformation of hepatocytes, whereas AFLP is defined by
    microvesicular steatosis.
  distinguishing_features:
  - AFLP typically shows hypoglycemia, marked coagulopathy, and hyperammonemia out of proportion to the transaminase rise.
  - Hypertension and proteinuria are usually absent in AFLP but usually present in HELLP.
  - Liver histology shows fatty transformation in AFLP and its explicit absence in HELLP.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical signs of AFLP vary and there is significant overlap in clinical and biochemical features"
    explanation: Establishes the substantial clinical and biochemical overlap that makes AFLP the principal differential.
  - reference: PMID:11924711
    reference_title: "Maternal death in pregnancy from HELLP syndrome. A report of three medico-legal autopsy cases with special reference to distinctive histopathological alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lack of fatty transformation of hepatocytes"
    explanation: The histological feature that separates HELLP from acute fatty liver of pregnancy.
- name: Thrombotic thrombocytopenic purpura
  description: >
    Shares microangiopathic hemolysis and thrombocytopenia. TTP is driven by ADAMTS13
    deficiency and VWF-platelet aggregation, a mechanistically distinct microangiopathy
    that does not resolve with delivery and requires plasma exchange.
  distinguishing_features:
  - Prominent neurologic involvement and severe ADAMTS13 deficiency favor TTP.
  - Failure to improve after delivery argues strongly against HELLP.
  disease_term:
    preferred_term: thrombotic thrombocytopenic purpura
    term:
      id: MONDO:0018896
      label: thrombotic thrombocytopenic purpura
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)"
    explanation: Names TTP among the serious conditions that mimic HELLP and require different therapy.
- name: Hemolytic uremic syndrome
  description: >
    Also a thrombotic microangiopathy; pregnancy-associated atypical HUS is
    complement-mediated and may be genuinely difficult to separate from HELLP, especially
    since a complement arm is proposed for HELLP itself. Persistent renal failure and
    failure to improve after delivery point to aHUS.
  distinguishing_features:
  - Predominant and persistent renal failure with dialysis requirement favors aHUS.
  - Persistence or worsening beyond the first postpartum days favors aHUS over HELLP.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)"
    explanation: Names HUS among the serious mimics of HELLP requiring a different therapeutic approach.
- name: Immune thrombocytopenic purpura
  description: >
    A common cause of thrombocytopenia in pregnancy. ITP produces isolated
    thrombocytopenia without hemolysis or transaminase elevation.
  distinguishing_features:
  - Isolated thrombocytopenia with normal LDH, transaminases, and smear.
  evidence:
  - reference: PMID:19245695
    reference_title: "The HELLP syndrome: clinical issues and management. A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other less common, but serious conditions that may mimic HELLP, include ITP"
    explanation: Names ITP among the conditions that may be mistaken for HELLP.
- name: Systemic lupus erythematosus and antiphospholipid syndrome
  description: >
    Both can produce a pregnancy microangiopathy resembling HELLP, and both are
    independently associated with HELLP - chronic inflammatory disease and lupus were more
    strongly associated with HELLP than with isolated preeclampsia in a nationwide cohort.
    The distinction is therefore often one of co-existence rather than exclusion.
  distinguishing_features:
  - Antiphospholipid antibodies, prior thrombosis, or established lupus point to a coexisting or alternative diagnosis.
  - Neurologic involvement, dialysis requirement, or absent DIC raise concern for an APS-associated microangiopathy.
  evidence:
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic inflammatory diseases and lupus were more associated with PE-HELLP than iPE."
    explanation: Population-scale evidence that lupus and chronic inflammatory disease are differentially associated with HELLP.
discussions:
- discussion_id: hellp_complement_causal_role
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >
    Is alternative-complement-pathway dysregulation a causal driver of HELLP syndrome in
    the subset of women who carry germline variants, or a bystander marker of the severe
    endothelial injury that HELLP shares with other thrombotic microangiopathies?
  attaches_to:
  - pathophysiology#Alternative Complement Pathway Dysregulation
  rationale: >
    The evidence is suggestive but does not settle direction. Germline
    alternative-pathway variants are enriched in HELLP cohorts and modified Ham testing is
    frequently positive, but the study is a single case-control series, complement
    activation is expected downstream of any severe endothelial injury, and the therapeutic
    evidence for C5 blockade is uncontrolled case reports in a condition that resolves on
    delivery. Resolving this determines whether eculizumab belongs on this entry as a
    treatment or only as a hypothesis.
  proposed_experiments:
  - experiment_id: hellp_c5_blockade_rct
    name: Randomized trial of C5 blockade in early-onset HELLP
    description: >
      A randomized trial of eculizumab or ravulizumab versus expectant management plus
      standard care in HELLP remote from term, with pregnancy prolongation and maternal
      organ-injury markers as endpoints, stratified by germline alternative-pathway
      genotype and baseline mHam status.
  - experiment_id: hellp_apc_variant_replication
    name: Replication of the germline variant enrichment in an independent cohort
    description: >
      Independent case-control sequencing of alternative-pathway complement genes in HELLP
      versus normotensive pregnancy and versus severe preeclampsia without HELLP, to test
      whether the enrichment is specific to HELLP or general to severe hypertensive
      disease of pregnancy.
  evidence:
  - reference: PMID:32986992
    reference_title: "Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings suggest that the inhibition of the terminal complement pathway, possibly through C5 blockade, may be an effective strategy to treat preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, but this strategy warrants further evaluation in clinical trials."
    explanation: The source's own statement that trial evaluation is still required, which is the gap this discussion records.
- discussion_id: hellp_distinct_entity_or_pe_variant
  kind: CONTROVERSY
  status: OPEN
  prompt: >
    Is HELLP a severe variant within the preeclampsia spectrum, or a distinct disease
    entity that merely co-occurs with preeclampsia?
  attaches_to:
  - pathophysiology#Maternal Endothelial Injury and Systemic Inflammatory Amplification
  rationale: >
    This is not a naming argument - it determines whether HELLP-specific mechanism nodes
    are warranted at all. Arguments for a variant: 70-80% of cases coexist with
    preeclampsia, the placental trigger appears shared, and ICD-10 codes HELLP as a
    subcode of preeclampsia (O14.2), which makes "HELLP without PE" unascertainable in
    administrative data. Arguments for a distinct entity: risk-factor profiles diverge
    (diabetes, chronic hypertension, and obesity track isolated preeclampsia while chronic
    inflammatory disease and lupus track HELLP), outcome dynamics diverge, and the
    liver-dominant thrombotic microangiopathy has no counterpart in uncomplicated
    preeclampsia. This entry takes the operational position of curating HELLP separately
    while modeling the shared upstream in a single compressed node.
  evidence:
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "iPE and PE with HELLP differ regarding their risk factors and types and dynamics of their major complications."
    explanation: Population-scale evidence for divergence, the strongest current argument for treating HELLP as more than a severity label.
  - reference: PMID:42502666
    reference_title: "Divergent Risk Factors and Outcomes in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Isolated Preeclampsia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, whether it represents a distinct condition or a severe variant within the PE spectrum has been debated."
    explanation: The source explicitly frames this as an unresolved debate rather than a settled question.
  - reference: PMID:23107053
    reference_title: "Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HELLP occurs in 0.2-0.8% of pregnancies and in 70-80% of cases it coexists with preeclampsia (PE)."
    explanation: >
      The high but incomplete coexistence rate is evidence on both sides: it supports the
      shared-spectrum view while leaving 20-30% of cases without preeclampsia.
- discussion_id: hellp_fao_metabolite_transfer
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >
    Are 3-hydroxy long-chain acyl metabolites actually transferred from an LCHAD-deficient
    fetoplacental unit into the maternal circulation at hepatotoxic concentrations, or is
    the maternal liver injury explained by some other consequence of the fetal genotype?
  attaches_to:
  - pathophysiology#Fetal Long-Chain Fatty-Acid Oxidation Defect
  rationale: >
    The genetic association is strong and allele-specific, but the mechanistic step
    routinely quoted for it - placental export of toxic 3-hydroxy intermediates into a
    heterozygous mother with reduced beta-oxidation reserve - is an inference. The cited
    study establishes genotype-phenotype correlation, not metabolite transfer. The
    causal edge from this node is therefore typed
    INDIRECT_UNKNOWN_INTERMEDIATES.
  proposed_experiments:
  - experiment_id: hellp_maternal_acylcarnitine_profiling
    name: Maternal acylcarnitine profiling stratified by fetal genotype
    description: >
      Serial maternal plasma long-chain 3-hydroxyacylcarnitine measurement across the third
      trimester in pregnancies stratified by fetal HADHA/HADHB genotype, testing whether
      maternal metabolite concentrations rise before and track with maternal hepatic
      injury.
  evidence:
  - reference: PMID:10352164
    reference_title: "A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women with acute liver disease during pregnancy may have a Glu474Gln mutation in long-chain hydroxyacyl-CoA dehydrogenase."
    explanation: >
      The study's own conclusion is stated as a genetic association; it does not assert
      metabolite transfer, which is the gap recorded here.
datasets:
- accession: geo:GSE66273
  title: Genome-wide analysis of placental gene expression in severe preterm preeclampsia
  data_type: MICROARRAY
  sample_count: 17
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:30135684
  notes: >-
    Selected as a DIRECT candidate by `just discover-datasets HELLP_Syndrome` and
    manually triaged: the GEO series summary states the placentas came from women with
    preterm severe preeclampsia "with or without HELLP syndrome", so HELLP cases are
    genuinely represented rather than the accession merely matching on a disease name.
    The GENE_ONLY candidates returned by the same search (HADHA-matched cardiomyocyte and
    murine Treg series) were rejected as Named Entity Confusion - they match the gene
    symbol cited on this entry's fetal fatty-acid-oxidation arm and have nothing to do
    with HELLP. Carries no evidence block, per the dataset-curation convention: the
    accession is verified to exist and be relevant, which is not the same as having an
    exact quotable finding about HELLP.
clinical_trials:
- name: NCT04103489
  phase: PHASE_I
  status: COMPLETED
  description: >
    Phase 1 study of eculizumab in early preterm HELLP syndrome (23-30 weeks estimated
    gestational age), testing whether terminal complement blockade halts or reverses
    disease progression. This is the registered trial behind the complement arm curated
    on this entry; its phase-1 design and small enrolment are why C5 blockade is recorded
    here as investigational rather than as an established treatment.
  target_phenotypes:
  - preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  - preferred_term: Hemolytic anemia
    term:
      id: HP:0001878
      label: Hemolytic anemia
  evidence:
  - reference: clinicaltrials:NCT04103489
    reference_title: "Eculizumab in HELLP Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This drug blocks a part of the immune system called complement. By blocking this part of the immune system, eculizumab may stop or reverse the progression of the HELLP syndrome disease."
    explanation: States the trial's complement-blockade rationale, which is the therapeutic hypothesis recorded in the complement discussion on this entry.
- name: NCT01138839
  phase: PHASE_III
  status: UNKNOWN
  description: >
    Multicentric, double-blind, placebo-controlled randomized trial of dexamethasone in
    Mississippi class 1 (HELLP I) syndrome. Registered to address exactly the
    maternal-benefit question the Cochrane review left open; its status is recorded as
    UNKNOWN because the registry record has not been updated.
  target_phenotypes:
  - preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: clinicaltrials:NCT01138839
    reference_title: "Dexamethasone Efficacy in HELLP I Syndrome, a Multicentric, Double-blind, Placebo-controlled, Randomized Clinical Trial"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to determine the efficacy of dexamethasone for treatment of HELLP I (hemolysis, elevated liver enzymes and low platelet count) syndrome."
    explanation: Confirms that the maternal efficacy of dexamethasone in severe HELLP is a registered, prospectively posed trial question rather than settled.
notes: >
  Scope and boundary decisions for this entry.

  (1) Relationship to Preeclampsia. HELLP is curated as its own Disease entry keyed on
  MONDO:0008585 while also appearing as a `has_subtypes` entry on kb/disorders/Preeclampsia.yaml.
  That file was deliberately NOT modified. The shared placental upstream is represented
  here by a single compressed trigger node rather than duplicated in full; the trophoblast
  invasion, spiral artery remodeling, and sFlt-1/VEGF detail lives on the Preeclampsia
  entry. The `hellp_distinct_entity_or_pe_variant` discussion records why this boundary is
  contestable.

  (2) Module conformance is deliberately node-qualified and partial. Two conformance
  assertions are made. `Microangiopathic Erythrocyte Fragmentation and Destruction`
  conforms to hemolytic_anemia_erythrocyte_destruction#Premature Erythrocyte Destruction,
  substituting a mechanical/extrinsic insult for that module's intrinsic-lesion arm; the
  module explicitly admits "mechanical (microangiopathic)" insults, so this is within
  scope. `Hepatic Sinusoidal Microthrombosis and Fibrin Deposition` conforms to
  thrombogenesis#Pathological Fibrin-Platelet Thrombus Formation and `Platelet Activation
  and Consumptive Thrombocytopenia` to thrombogenesis#Platelet Adhesion, Activation, and
  Aggregation. The thrombogenesis module places VWF-platelet microangiopathy such as TTP
  out of scope "unless a distinct conventional thrombin/fibrin thrombosis branch is
  explicitly evidenced" - that condition is met here by two independent sources reporting
  fibrin deposition and microthrombus formation in the hepatic sinusoids, including
  autopsy-confirmed intrahepatic fibrin networks. No conformance is asserted to the
  module's Virchow-triad, occlusion/ischemia, or embolization nodes.

  (3) Fetal fatty-acid-oxidation entries were not modified. The LCHAD/MTP/CPT1A
  association is cited from the maternal side only; kb/disorders/Long-Chain_3-Hydroxyacyl-CoA_Dehydrogenase_Deficiency.yaml,
  kb/disorders/Mitochondrial_Trifunctional_Protein_Deficiency.yaml, and
  kb/disorders/Carnitine_Palmitoyltransferase_1A_Deficiency.yaml already record it from
  the fetal side and were left untouched.

  (4) MONDO records "PEE1" and "PREECLAMPSIA/eclampsia 1" as RELATED synonyms of
  MONDO:0008585. These are OMIM susceptibility-locus labels, not names for HELLP, and were
  not used as search terms during curation - a deliberate named-entity-confusion
  precaution given that HELLP sits in a numbered/eponym-adjacent naming neighbourhood.

  (5) Low-dose aspirin prophylaxis is deliberately not curated as a HELLP treatment.
  Guideline-based low-dose aspirin started early in pregnancy is offered to women at
  elevated preeclampsia risk and may reduce some HELLP events as a consequence, but there
  is no evidence that it prevents HELLP specifically; the deep-research report says so
  explicitly. Recording it here would import a preeclampsia-level preventive as though it
  were HELLP-directed, which is exactly the boundary drawn in item (1). It belongs on
  kb/disorders/Preeclampsia.yaml, which was not modified for this entry.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 17 citations 2026-08-18T21:07:32.718445

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: HELLP Syndrome
MONDO ID: (if available)
Category: Complex

Research Objectives

Please provide a comprehensive research report on HELLP Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

HELLP syndrome: disease-characteristics research report

Scope. HELLP is an obstetric emergency rather than a classical monogenic disease. The strongest HELLP-specific evidence concerns clinical diagnosis, placental/endothelial pathology, and complement activation; much newer omics literature studies preeclampsia broadly and cannot automatically be generalized to HELLP. Publication dates and URLs are supplied for the principal sources. Where a requested field is unsupported or inapplicable, this is stated explicitly.

domain	best-supported finding	evidence type/strength	key ontology suggestions
Definition / criteria	HELLP syndrome is the severe microangiopathic form of hypertensive disease of pregnancy, defined by hemolysis, elevated liver enzymes, and low platelets; Tennessee criteria require hemolysis, AST >70 IU/L and/or LDH >600 IU/L or bilirubin >1.2 mg/dL, and platelets <100 × 10^9/L; it typically occurs after 20 weeks or immediately postpartum and improves after placental delivery (NCT07377786 chunk 1, burwick2022complementactivationand pages 7-11)	Human clinical/trial registry + peer-reviewed review; moderate-strong for diagnostic criteria	MONDO: HELLP syndrome (MONDO:0008585); MeSH: HELLP Syndrome (D017359); HPO: Hemolytic anemia, Elevated hepatic transaminases, Thrombocytopenia, Hypertension, Proteinuria
Epidemiology	Global pooled prevalence was 0.39% (95% CI 0.16–0.72) across 9 studies/133,611 participants, with regional variation and higher prevalence in low-income settings; one contemporary trial record notes occurrence up to 0.9% of pregnancies and severe maternal/perinatal mortality in historical literature (veraponce2025globalprevalenceof pages 1-2, NCT07377786 chunk 1)	Systematic review/meta-analysis + registry background; moderate, but HELLP estimate is limited by small study pool	ICD/MeSH pregnancy-hypertension grouping; HPO: Maternal morbidity, Fetal death
Pathophysiology	Best-supported model: abnormal placentation/poor spiral artery remodeling → placental ischemia/hypoxia → trophoblast injury, anti-angiogenic factor excess (sFLT1), complement activation (especially terminal pathway C5a/C5b-9), endothelial injury, platelet activation/consumption, microangiopathic hemolysis, liver injury, and multiorgan dysfunction; placental C5b-9 and sFLT1 are associated, and disease improves after placental removal (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11, burwick2022complementactivationand pages 11-15)	Mixed human placental, biomarker, in vitro, and animal evidence; strong for placental/angiogenic role, moderate for complement-causal contribution	GO: angiogenesis, complement activation, endothelial cell activation, platelet activation, apoptotic process, response to hypoxia; CL: trophoblast cell, monocyte, endothelial cell, platelet; UBERON: placenta, liver, kidney
Genetics	HELLP is not a Mendelian disorder, but complement regulatory variants are enriched in subsets: reported MCP/CD46 variants in ~8% of preeclampsia/HELLP cohorts, CFH mutations ~1.2%, CFI ~4.2%; in one small series, complement variants/CFHR deletions were found in 45% (5/11) of HELLP cases; fetal fatty-acid oxidation defects are historically discussed as overlap/association evidence rather than established common cause of HELLP (burwick2022complementactivationand pages 11-15, burwick2022complementactivationand pages 15-19, NCT04103489 chunk 1)	Human association/candidate-gene evidence; moderate to weak because cohorts are small and heterogeneous	HGNC genes: CD46/MCP, CFH, CFI, CFHR1, CFHR3; GO: regulation of complement activation; note multifactorial/polygenic rather than monogenic inheritance
Diagnosis / differential	Diagnosis is laboratory-clinical and overlaps with severe preeclampsia, acute fatty liver of pregnancy, TTP, and atypical HUS; distinguishing features rely on hemolysis pattern, liver injury, thrombocytopenia, kidney injury severity, ADAMTS13 for TTP, and persistent postpartum TMA/complement-mediated disease for aHUS rather than resolving HELLP (markin2024thromboticmicroangiopathyin pages 5-6, NCT04103489 chunk 1)	Human clinical review/trial rationale; moderate	HPO: Right upper quadrant pain, Nausea, Vomiting, Acute kidney injury, Disseminated intravascular coagulation; NCIT/MeSH differential concepts: Thrombotic Microangiopathy, Acute Fatty Liver of Pregnancy, Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome
Treatment	Current management remains supportive plus expedited delivery when maternal/fetal status warrants: blood-pressure control, magnesium seizure prophylaxis, corticosteroids for fetal lung maturity when preterm, transfusion support as needed, and delivery as definitive treatment; maternal dexamethasone has been studied for HELLP-I lab recovery/hospitalization but remains controversial; complement blockade with eculizumab is investigational in early preterm HELLP (ng2024biomarkersandpoint pages 1-2, NCT01138839 chunk 1, NCT04103489 chunk 1)	Guidelines/review-level standard care + interventional trial records; strong for delivery/supportive care, weak-emerging for eculizumab	NCIT: Delivery, Magnesium Sulfate, Antihypertensive Therapy, Dexamethasone, Platelet Transfusion, Plasma Transfusion, Eculizumab
Prognosis	HELLP is associated with major maternal complications including eclampsia, DIC, liver rupture, placental abruption, stroke, pulmonary and kidney failure; fetal risks include IUFD, NICU admission, low Apgar/acidemia, and iatrogenic prematurity; biologic recovery usually begins after delivery and often occurs within about 1 week postpartum in uncomplicated recovery (NCT07377786 chunk 1, NCT07377786 chunk 2, NCT06758960 chunk 1)	Human observational/trial-registry evidence; moderate	HPO: Disseminated intravascular coagulation, Hepatic rupture, Placental abruption, Stroke, Pulmonary edema/respiratory failure, Acute kidney injury, Intrauterine fetal death
Research gaps	Major gaps include lack of validated HELLP-specific biomarkers, limited large genomic studies, poor separation of HELLP from adjacent pregnancy TMAs, sparse HELLP-specific multi-omics/single-cell data, uncertainty about which patients have complement-driven disease, and very small interventional studies for targeted therapy such as anti-C5 blockade (cao2024placentaloriginsof pages 1-2, NCT04103489 chunk 1, burwick2022complementactivationand pages 15-19)	Evidence synthesis across reviews and trial landscape; strong for existence of gaps	GO/ontology curation needs: complement dysregulation, placental cell-state atlases, disease subclassification within hypertensive disorders of pregnancy

Table: This compact table summarizes the best-supported findings for HELLP syndrome across clinical definition, epidemiology, mechanisms, genetics, diagnosis, treatment, prognosis, and research gaps. It is useful as a quick evidence map for building a disease knowledge-base entry.

1. Disease information

HELLP is an acronym for hemolysis, elevated liver enzymes, and low platelet count. It is a pregnancy-associated thrombotic microangiopathic syndrome generally considered a severe phenotype within the preeclampsia spectrum, although hypertension or proteinuria may not be prominent in every presentation. The defining processes are microangiopathic hemolysis, hepatocellular injury, and platelet consumption. Removal of the placenta at delivery is followed by improvement in most true HELP/HELLP-spectrum cases, supporting a placenta-mediated disorder. (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11)

Identifiers and synonyms

MONDO: MONDO:0008585, HELLP syndrome. Open Targets currently lists no validated associated target for this MONDO disease, underscoring that there is no established single causal gene or approved molecular target. (OpenTargets Search: HELLP syndrome)
MeSH: D017359, HELLP Syndrome. (NCT01138839 chunk 1)
OMIM/Orphanet: no dedicated Mendelian OMIM entry or well-supported monogenic Orphanet disease identity was established in the retrieved evidence.
ICD: coding varies by jurisdiction and trimester; HELLP is usually coded within preeclampsia/severe preeclampsia categories rather than as a universally consistent standalone code. Local ICD-10-CM/ICD-11 release validation is required before database loading.
Synonyms: HELLP syndrome; hemolysis–elevated liver enzymes–low platelet count syndrome; HELLP variant of severe preeclampsia; complete/classic HELLP. “Partial HELLP” is older and inconsistent terminology, often overlapping preeclampsia with severe features.
Category: complex, multifactorial pregnancy disorder; acquired, placenta-associated thrombotic microangiopathy.

This report synthesizes aggregated disease-level evidence from reviews, cohorts, meta-analysis, and trial registrations. It is not derived from an individual EHR.

2. Etiology, risk, and protection

Causal framework

No single necessary and sufficient cause is known. The prevailing causal model is: abnormal placentation and/or placental stress → ischemia/hypoxia and trophoblast injury → release of antiangiogenic and inflammatory factors → systemic endothelial activation → platelet aggregation/consumption, red-cell fragmentation, hepatic sinusoidal microvascular injury, and multiorgan dysfunction. Delivery removes the principal upstream organ but does not instantly reverse established endothelial and coagulation injury. (burwick2022complementactivationand pages 7-11)

Risk factors

HELLP-specific quantitative risk-factor evidence is less robust than for preeclampsia. Clinically relevant risk enrichment includes prior HELLP or preeclampsia, chronic hypertension, antiphospholipid syndrome, multifetal pregnancy, obesity, diabetes, renal disease, autoimmune disease, advanced maternal age, and assisted reproduction. These are susceptibility factors, not deterministic causes. Socioeconomic disadvantage and reduced access to prenatal care can delay recognition and increase severe outcomes; these are health-system/environmental modifiers rather than direct molecular causes. A 2024 review notes disproportionate preeclampsia morbidity across racial and socioeconomic groups, but these patterns should not be interpreted as biological race effects. (ng2024biomarkersandpoint pages 1-2)

A mechanistically informative gene–environment observation is the interaction between obesity and complement activation: in a prospective preeclampsia cohort, BMI >30 kg/m² plus elevated early-pregnancy Bb produced adjusted odds ratio 10.0 (95% CI 3.3–30), while obesity plus elevated C3a produced adjusted odds ratio 8.8 (95% CI 3–24). This is preeclampsia-spectrum—not HELLP-specific—evidence. (burwick2022complementactivationand pages 15-19)

Protective factors and prevention

There is no proven HELLP-specific vaccine, dietary intervention, or protective genotype. In patients at elevated preeclampsia risk, guideline-based low-dose aspirin started early in pregnancy moderately reduces preeclampsia risk and may consequently reduce some HELLP events, but it is not a guaranteed HELLP preventive treatment. Calcium supplementation is relevant in populations with low dietary calcium under applicable obstetric guidance. Blood-pressure optimization, management of diabetes/renal disease, smoking avoidance, healthy prepregnancy weight, and early prenatal surveillance are reasonable risk-reduction strategies, not established disease-specific cures. (ng2024biomarkersandpoint pages 1-2, cao2024placentaloriginsof pages 1-2)

3. Phenotypes

HELLP is adult-onset by definition because it occurs during pregnancy or puerperium. It is usually acute and progressive over hours to days, most often in the third trimester and frequently before 36 weeks; it can first manifest postpartum. A contemporary trial synopsis reports malaise and right-upper-quadrant pain in approximately 90% each, although these figures derive from cited historical literature rather than the trial itself. (NCT07377786 chunk 1)

Phenotype	Type/course	Suggested HPO term
Microangiopathic hemolytic anemia; schistocytes, high LDH, low haptoglobin, indirect hyperbilirubinemia	Defining laboratory abnormality; acute/progressive	Hemolytic anemia, HP:0001878; Schistocytosis
Elevated AST/ALT, hepatic tenderness	Defining laboratory/sign; variable to severe	Elevated hepatic transaminases, HP:0002910
Thrombocytopenia	Defining laboratory abnormality; severity tracked serially	Thrombocytopenia, HP:0001873
Right-upper-quadrant/epigastric pain	Common symptom; may herald hepatic injury	Abdominal pain, HP:0002027
Nausea/vomiting, malaise, headache or visual symptoms	Nonspecific symptoms; episodic/progressive	Nausea, HP:0002018; Vomiting, HP:0002013; Headache, HP:0002315
Hypertension and proteinuria	Frequent but not indispensable to the laboratory triad	Hypertension, HP:0000822; Proteinuria, HP:0000093
Acute kidney injury, pulmonary edema, cerebral symptoms/eclampsia	Severe end-organ phenotypes	Acute kidney injury, HP:0001919; Pulmonary edema, HP:0100598; Seizure, HP:0001250
DIC, placental abruption, hepatic hematoma/rupture, stroke	Life-threatening complications	Disseminated intravascular coagulation, HP:0005521; Placental abruption; Stroke, HP:0001297
Fetal growth restriction, prematurity, fetal distress/death	Fetal/placental consequences	Intrauterine growth retardation, HP:0001511; Premature birth, HP:0001622; Intrauterine fetal death, HP:0003826

Quality-of-life research using HELLP-specific EQ-5D/SF-36 instruments is sparse. Immediate impact is severe—hospitalization, ICU care, urgent delivery, pain, loss of pregnancy autonomy, and neonatal intensive care. Longer-term impacts may include post-traumatic stress, anxiety, grief after fetal loss, and cardiovascular surveillance burden, but precise phenotype-specific frequencies were not established in the retrieved sources.

4. Genetic and molecular information

No established causal gene

HELLP does not follow Mendelian inheritance, and routine designation of any variant as “pathogenic for HELLP” is not justified. Open Targets reports zero validated disease-target associations for MONDO:0008585. Consequently, WES, WGS, gene panels, CMA, karyotyping, FISH, mitochondrial DNA, and repeat-expansion testing are not routine HELLP diagnostics. (OpenTargets Search: HELLP syndrome)

Susceptibility evidence

Complement-regulatory variants may define a subset with heightened complement activation. Across heterogeneous preeclampsia/HELLP studies, CD46/MCP variants occurred in about 8% of 264 cases, CFH mutations in 1.2%, and CFI mutations in 4.2%. Reported functional variants include CFH p.Arg303Gln, affecting C3b binding/decay acceleration, and CFI p.Arg345Gln (c.1034G>A), with defective C3b/C4b cofactor activity. In one very small series, complement variants or CFHR deletions occurred in 5/11 (45%) HELLP cases and 3/14 (21%) severe-feature cases; homozygous CFHR1–CFHR3 or CFHR1 deletions could favor C5b-9 formation. These estimates require replication and are not population penetrance values. (burwick2022complementactivationand pages 11-15, burwick2022complementactivationand pages 15-19)

The relevant variants are germline susceptibility alleles/deletions, not somatic mutations. Penetrance is incomplete; paternal/fetal complement status is generally unmeasured. No established protective allele, anticipation, germline mosaicism, founder mutation, carrier frequency, or consanguinity effect is known for HELLP. (burwick2022complementactivationand pages 15-19)

Fetal HADHA/HADHB fatty-acid-oxidation defects are strongly linked to acute fatty liver of pregnancy and have historically been associated with some HELLP-like maternal liver disease. They should not be entered as common causal HELLP genes. If profound maternal hypoglycemia, hepatic failure, or a neonatal fatty-acid oxidation disorder raises concern, targeted maternal–fetal metabolic/genetic evaluation may be appropriate.

Epigenetics and chromosomal abnormalities

Preeclampsia studies report placental DNA-methylation and regulatory-RNA changes, but no HELLP-specific epigenetic lesion is clinically validated. No recurrent aneuploidy, translocation, inversion, or pathogenic copy-number change defines HELLP.

5. Environmental, lifestyle, and infectious information

No toxin, radiation exposure, pollutant, occupational agent, bacterium, virus, fungus, or parasite is established as a direct cause. Infection and inflammatory stress can activate complement and endothelium and may serve as nonspecific triggers in susceptible pregnancies, but HELLP is not infectious or transmissible. Lifestyle associations largely track preeclampsia risk; no evidence supports alcohol, smoking, diet, or exercise as a singular HELLP cause. Limited prenatal access is an important real-world determinant of delayed diagnosis and worse outcome. (ng2024biomarkersandpoint pages 1-2, veraponce2025globalprevalenceof pages 1-2)

6. Mechanism and pathophysiology

Causal chain and hierarchy

Upstream placental dysfunction: deficient spiral-artery remodeling and impaired uteroplacental perfusion produce hypoxia, oxidative stress, inflammation, apoptosis/necrosis, and trophoblast shedding.
Angiogenic imbalance: stressed trophoblasts release excess soluble FLT1 (sFlt-1), which sequesters VEGF and PlGF; soluble endoglin may add TGF-β pathway antagonism. Reduced VEGF/PlGF signaling promotes systemic endothelial dysfunction, hypertension, proteinuria, and glomerular endotheliosis. (cao2024placentaloriginsof pages 1-2, burwick2022complementactivationand pages 7-11)
Complement amplification: normal pregnancy has regulated complement activation. In HELLP/preeclampsia, activation exceeds regulation; placental C4d and terminal C5b-9 deposits increase. C5a stimulates monocytes/trophoblasts to increase sFlt-1, and C5b-9 can injure trophoblasts, creating a feed-forward angiogenic–complement loop. (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11)
Systemic endothelial/TMA phase: endothelial activation exposes prothrombotic surfaces; platelet adhesion and aggregation release thromboxane and serotonin, promoting vasospasm and further platelet consumption. Erythrocytes fragment while traversing narrowed, fibrin-rich microvessels, causing schistocytes, LDH elevation, low haptoglobin, and bilirubin elevation. (NCT07377786 chunk 1)
Organ injury: hepatic sinusoidal obstruction, ischemia, hemorrhage, and hepatocyte injury elevate AST/ALT and cause RUQ pain; severe cases develop subcapsular hematoma or rupture. Renal endothelial injury causes proteinuria/AKI; cerebral and pulmonary endothelial dysfunction can cause seizures, stroke, or edema.
Resolution: placental delivery stops the principal upstream stimulus, but laboratory abnormalities can transiently worsen postpartum before recovering. Persistence or worsening beyond the expected postpartum window raises concern for TTP, complement-mediated aHUS, CAPS, or another TMA. (markin2024thromboticmicroangiopathyin pages 5-6, burwick2022complementactivationand pages 7-11)

Suggested GO biological-process terms: response to hypoxia (GO:0001666), angiogenesis (GO:0001525), regulation of complement activation (GO:0030449), complement activation (GO:0006956), endothelial-cell activation, platelet activation (GO:0030168), coagulation (GO:0050817), inflammatory response (GO:0006954), apoptotic process (GO:0006915), oxidative-stress response (GO:0006979).

Cell Ontology suggestions: trophoblast cell (CL:0000351), syncytiotrophoblast, extravillous trophoblast, vascular endothelial cell (CL:0000115), monocyte (CL:0000576), macrophage (CL:0000235), neutrophil (CL:0000775), platelet (CL:0000233), erythrocyte (CL:0000232), hepatocyte (CL:0000182), glomerular endothelial cell.

Subcellular/biochemical compartments: extracellular complement cascade; endothelial plasma membrane; platelet granules; mitochondrial oxidative-stress pathways; hepatocyte cytoplasm; terminal complement membrane-attack complex. Suggested GO-CC: extracellular region (GO:0005576), plasma membrane (GO:0005886), membrane attack complex (GO:0005579), mitochondrion (GO:0005739).

Molecular profiling and advanced technologies

The 2024 placental multi-omics review identifies FLT1 as a reproducible preeclampsia signature gene and describes transcriptomic, proteomic, fetal-GWAS, and single-cell evidence implicating trophoblast and placental vascular cell states. It also stresses substantial interstudy inconsistency, small samples, and inadequate subtype validation. These findings are promising but mostly not HELLP-specific. (cao2024placentaloriginsof pages 1-2)

Human/in-vitro/animal complement evidence is more HELLP-relevant: C5a stimulation increases trophoblast sFLT1 transcripts and reduces PlGF; placental C5b-9 correlates with sFLT1 protein (r=0.59, P=0.01); C5a impairs trophoblast migration/tube formation and C5a-receptor inhibition reverses these effects. Mouse experiments show C5a-driven monocyte sFlt-1 production, placental dysfunction, and fetal death, preventable with C5aR inhibition. (burwick2022complementactivationand pages 11-15)

In active severe preeclampsia, urinary C5a rose approximately fivefold and C5b-9 more than fourfold; urinary C5b-9 was detected in 96% of severe cases in cited cohorts. These remain investigational biomarkers and were not validated as standalone HELLP tests. (burwick2022complementactivationand pages 15-19)

There is no validated HELLP clinical diagnostic based on RNA-seq, proteomics, metabolomics, lipidomics, spatial transcriptomics, cfDNA, or CRISPR screening.

7. Anatomical structures affected

Primary: placenta/uteroplacental circulation—chorionic villi, syncytiotrophoblast, extravillous trophoblast, decidua, spiral arteries. Suggested UBERON: placenta (UBERON:0001987), decidua, uterine artery.
Defining maternal organ: liver—hepatic sinusoids, periportal parenchyma, subcapsular region. Suggested UBERON: liver (UBERON:0002107).
Hematovascular: systemic microvascular endothelium, erythrocytes, platelets, coagulation system.
Secondary: kidney/glomerulus (UBERON:0002113), brain (UBERON:0000955), lung (UBERON:0002048), heart/circulation.
Fetal: fetal placenta and fetus are secondarily affected through uteroplacental insufficiency and medically indicated prematurity.

Lateralization is generally not applicable. Hepatic hematoma or rupture may be focal and is often reported in the right lobe, but no defining laterality exists.

8. Temporal development

Onset is typically acute after 20 weeks, predominantly in the third trimester; cases may develop in the immediate postpartum period. Symptoms can be vague initially and laboratory deterioration rapid. The most clinically useful stages are not formal disease stages but: suspected disease, complete/partial laboratory syndrome, severe maternal or fetal complication, delivery, and postpartum resolution. (markin2024thromboticmicroangiopathyin pages 5-6, NCT07377786 chunk 1)

Serial platelet count, AST/ALT, LDH, bilirubin, creatinine, coagulation studies, urine output, blood pressure, symptoms, and fetal status are crucial. A prospective 2023–2025 cohort, NCT06758960, followed platelets, LDH, and liver enzymes daily for ten days around delivery, illustrating current interest in biological progression/regression. (NCT06758960 chunk 1)

Typical recovery begins after delivery and often occurs within approximately one week. Failure to improve within 48–72 hours, or worsening renal-predominant TMA, should prompt urgent reevaluation. HELLP is generally self-limited after pregnancy rather than lifelong, but recurrence and long-term cardiometabolic risk remain.

9. Inheritance and population

A 2025 systematic review/meta-analysis of nine HELLP studies (133,611 participants) estimated global prevalence at 0.39% (95% CI 0.16–0.72); the authors explicitly cautioned that the estimate rests on a small study pool. Higher prevalence was observed in lower-income regions, likely reflecting differences in risk structure, diagnostic criteria, and healthcare access. (veraponce2025globalprevalenceof pages 1-2)

Other sources commonly cite approximately 0.1–0.9% of pregnancies, with higher occurrence among severe preeclampsia. NCT04103489 uses 0.1–0.2%, while NCT07377786 cites up to 0.9%, demonstrating criterion and population heterogeneity. (NCT07377786 chunk 1, NCT04103489 chunk 1)

The affected pregnant patient is female; fetal/neonatal consequences affect both sexes. This is multifactorial/polygenic susceptibility rather than AD, AR, X-linked, or mitochondrial inheritance. No established penetrance, anticipation, carrier frequency, founder effect, or consanguinity effect exists. Family history of preeclampsia may increase risk but does not constitute simple inheritance.

Recurrence in a later pregnancy is clinically meaningful, but exact rates vary by study, gestational age, and whether recurrence means HELLP specifically or any hypertensive disorder. Prior HELLP warrants preconception counseling, low-dose aspirin when indicated, baseline renal/liver/platelet assessment, and high-risk obstetric surveillance.

10. Diagnostics

Core laboratory diagnosis

The widely used Tennessee complete-HELLP criteria require all three components:

Microangiopathic hemolysis: abnormal peripheral smear/schistocytes, low haptoglobin, elevated LDH; bilirubin >1.2 mg/dL may support hemolysis.
Liver injury: AST ≥70 IU/L or aminotransferases at least twice the upper reference limit.
Platelets <100 × 10⁹/L.

LDH ≥600 IU/L is commonly used. Thresholds and whether LDH is assigned to hemolysis or liver injury vary by framework. (markin2024thromboticmicroangiopathyin pages 5-6, NCT07377786 chunk 1)

The Mississippi classification grades severity principally by nadir platelet count: class 1 ≤50 × 10⁹/L, class 2 >50 to ≤100 × 10⁹/L, and class 3 >100 to ≤150 × 10⁹/L, together with biochemical evidence of liver injury/hemolysis. Laboratories and guidelines should retain their exact local definitions because published cutoffs differ.

Recommended work-up

CBC with serial platelets; peripheral smear; LDH; haptoglobin; total/direct bilirubin; AST/ALT; creatinine/electrolytes; urinalysis/protein quantification; PT, aPTT and fibrinogen if bleeding/DIC is suspected; blood type and crossmatch; frequent blood pressure and neurologic assessment; fetal heart-rate monitoring and obstetric ultrasound as clinically indicated. Imaging is not required for diagnosis, but urgent liver ultrasound, CT, or MRI is appropriate for severe RUQ/shoulder pain, shock, falling hematocrit, or suspected hematoma/rupture.

PlGF or sFlt-1/PlGF can aid assessment of suspected preeclampsia in some jurisdictions but does not replace HELLP blood tests. Point-of-care and omics biomarkers remain incompletely validated. (ng2024biomarkersandpoint pages 1-2, cao2024placentaloriginsof pages 1-2)

Differential diagnosis

TTP: marked thrombocytopenia and neurologic features; severe ADAMTS13 activity deficiency supports TTP. Delivery alone does not resolve it; urgent plasma exchange is required.
Complement-mediated aHUS: renal-predominant TMA, often postpartum, severe AKI, and failure to resolve after delivery; complement genetics can support but normal testing does not exclude it.
Acute fatty liver of pregnancy: hypoglycemia, coagulopathy, hyperbilirubinemia, encephalopathy, ammonia elevation, and diffuse hepatic dysfunction are more prominent; overlap occurs.
DIC: prolonged PT/aPTT, low fibrinogen, markedly increased fibrin-degradation products, usually secondary to abruption, hemorrhage, sepsis, fetal death, or severe HELLP.
Other: antiphospholipid syndrome/CAPS, lupus flare, viral hepatitis, biliary disease, sepsis, immune thrombocytopenia, gestational thrombocytopenia, drug-induced liver injury.

True HELLP generally improves after delivery, whereas persistent postpartum TMA should trigger ADAMTS13 testing, hemolysis reassessment, nephrology/hematology input, and evaluation for aHUS. (burwick2022complementactivationand pages 11-15, markin2024thromboticmicroangiopathyin pages 5-6)

No asymptomatic population HELLP screen, newborn screen, carrier screen, or cascade genetic test is recommended.

11. Outcome and prognosis

HELLP can cause eclampsia, DIC, placental abruption, acute kidney injury, pulmonary edema/respiratory failure, stroke, hepatic hematoma or rupture, hemorrhage, ICU admission, and death. Fetal outcomes are driven largely by placental insufficiency, abruption, fetal distress, growth restriction, and gestational age at indicated delivery; outcomes include NICU admission, acidemia/low Apgar score, stillbirth, and complications of prematurity. (NCT07377786 chunk 1, NCT07377786 chunk 2)

A trial registration cites historical maternal and perinatal mortality as high as 23.1% and 56.9%, respectively. These are not contemporary universal rates and likely reflect selected severe cases and resource-limited settings; they should not be used as baseline prognosis in well-resourced modern care. (NCT07377786 chunk 1)

Most patients recover hematologically and hepatically after delivery. Prognosis worsens with very early gestational age, platelet class 1, DIC, hepatic rupture, stroke, severe AKI, placental abruption, delayed diagnosis, and failure of TMA to resolve postpartum. Survivors of preeclampsia-spectrum disease have increased later cardiovascular, hypertensive, metabolic, and renal risk; postpartum transition to primary care and periodic blood-pressure, lipid, glucose, renal-function, and cardiovascular-risk assessment are warranted.

12. Treatment and real-world implementation

HELLP requires urgent management in a hospital with obstetric, anesthesia, neonatal, transfusion, and critical-care capability.

Stabilize: two large-bore IV lines, serial laboratory tests, blood-bank preparation, strict fluid balance, oxygen if needed, and continuous maternal/fetal assessment.
Treat severe hypertension: rapid-acting IV labetalol, IV hydralazine, or immediate-release oral nifedipine under obstetric protocols to reduce stroke risk.
Prevent/treat seizures: magnesium sulfate unless contraindicated, with dose adjustment/monitoring in renal impairment.
Delivery: definitive therapy is delivery after initial maternal stabilization. Immediate delivery is indicated for uncontrolled severe hypertension, eclampsia, DIC, abruption, nonreassuring fetal status, pulmonary edema, progressive renal/hepatic injury, suspected liver rupture, or other instability. Brief delay for antenatal corticosteroids may be considered only in carefully selected stable preterm cases at an appropriate center; HELLP is not ordinarily managed by prolonged expectant care. (ng2024biomarkersandpoint pages 1-2, burwick2022complementactivationand pages 7-11)
Route: vaginal delivery is acceptable when obstetrically feasible and timely; cesarean delivery is based on gestational age, cervical status, fetal condition, and urgency—not HELLP alone.
Fetal lung maturation: betamethasone or dexamethasone for anticipated preterm birth according to gestational-age guidance. This is distinct from high-dose maternal dexamethasone intended to alter HELLP laboratory recovery.
Blood products: red cells for symptomatic anemia/hemorrhage; platelets for active bleeding, very low count, or procedures according to local thresholds; plasma/cryoprecipitate for DIC or factor/fibrinogen deficiency. Transfusion should be individualized.
Anesthesia: neuraxial anesthesia depends on platelet count trend, coagulation status, bleeding history, and anesthesiology risk assessment. No single platelet cutoff is universally safe.
Postpartum: continue close monitoring because platelets and enzymes may worsen initially; assess hemorrhage, renal function, pulmonary edema, neurologic symptoms, and blood pressure.

Maternal corticosteroid controversy. A phase 3 randomized protocol, NCT01138839, tested IV dexamethasone 10 mg every 12 hours in Mississippi class-1 HELLP, with hospitalization and platelet/liver-enzyme recovery outcomes. The registry notes that an earlier subgroup signal for faster platelet recovery was unplanned. High-dose corticosteroids should therefore not be represented as proven definitive maternal therapy. (NCT01138839 chunk 1)

Complement inhibition. NCT04103489 was a completed, open-label phase 1 study of eculizumab in HELLP at 23–30 weeks, enrolling only three participants and evaluating laboratory change and pregnancy latency. This is biologically plausible because most studied HELLP samples showed alternative-pathway activation suppressible by anti-C5 in vitro, but the study is far too small to establish efficacy or routine use. Eculizumab remains investigational for HELLP; aHUS is a separate approved indication. (NCT04103489 chunk 1)

Suggested NCIt intervention concepts: Therapeutic delivery/induction of labor; cesarean section; magnesium sulfate; antihypertensive therapy; labetalol; hydralazine; nifedipine; betamethasone; dexamethasone; red-blood-cell transfusion; platelet transfusion; fresh-frozen plasma transfusion; cryoprecipitate; eculizumab.

Gene therapy, cell therapy, RNA therapy, CRISPR, immunotherapy other than investigational complement blockade, and genotype-guided pharmacotherapy have no current clinical role.

13. Prevention

Primary: preconception optimization of chronic hypertension, diabetes, renal disease, obesity, and autoimmune disease; early prenatal care; guideline-based aspirin for high-risk patients; calcium where dietary intake is low.
Secondary: early recognition through blood-pressure measurement, symptom education, urine assessment, and prompt CBC/liver/hemolysis testing when symptoms or hypertension arise. There is no general-population HELLP biomarker screen.
Tertiary: immediate stabilization and delivery when indicated; seizure/stroke prevention; transfusion and organ support; postpartum TMA reassessment; cardiovascular and renal follow-up.
Counseling: explain recurrence risk, warning symptoms (severe headache, visual symptoms, epigastric/RUQ pain, dyspnea, bleeding, reduced fetal movement), aspirin planning, and need for maternal–fetal medicine surveillance.
Public health: improve prenatal access, emergency referral pathways, laboratory/transfusion capacity, and postpartum follow-up, particularly in low-resource settings where prevalence and severe outcomes are higher. (ng2024biomarkersandpoint pages 1-2, veraponce2025globalprevalenceof pages 1-2)

Vaccination and environmental decontamination are not HELLP-specific preventive measures.

14. Other species and natural disease

No validated naturally occurring veterinary disorder equivalent to the complete human HELLP syndrome was identified. HELLP depends on human pregnancy-specific placentation, maternal spiral-artery remodeling, and obstetric definitions; therefore it is not considered zoonotic, contagious, or transmissible across species. No breed/VBO association is established. Orthologs of complement, angiogenic, and coagulation genes are evolutionarily conserved, permitting mechanistic experiments, but similarity of pathway is not evidence of natural HELLP in animals.

15. Model organisms and experimental systems

No model reproduces the complete human triad, gestational timing, placental pathology, and postpartum resolution with high fidelity.

Rodent placental-ischemia/reduced uterine perfusion models: reproduce hypertension, endothelial dysfunction, angiogenic imbalance, fetal growth restriction, and sometimes liver/platelet changes. They are useful for upstream placental mechanisms but incompletely reproduce HELLP.
Complement-dysregulation/antiphospholipid models: C5a can drive monocyte sFlt-1 production, placental dysfunction, and fetal loss; C5aR inhibition prevents selected phenotypes. These support a causal complement–angiogenic link, not a universal complement etiology. (burwick2022complementactivationand pages 11-15)
C1q-deficient mice: develop preeclampsia-like hypertension, proteinuria, glomerular endotheliosis, oxidative stress, and increased sFlt-1/PlGF ratio; they are placentation/complement models rather than faithful HELLP models.
BPH/5 mouse: spontaneous preeclampsia-like model in which angiogenic imbalance can precede placental complement deposition; useful for temporal pathway studies.
In-vitro human trophoblast/endothelial systems: hypoxia and C5b-9 increase trophoblast injury; C5a reduces migration and tube formation and increases sFLT1. Primary trophoblast, placental explant, endothelial coculture, organoid, and placenta-on-chip systems improve human relevance but lack whole-body maternal coagulation, liver, kidney, and fetal physiology. (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11, burwick2022complementactivationand pages 11-15)

Suggested model resources include MGI, RGD, IMSR/MMRRC, GEO/SRA, Cellosaurus, and placental single-cell atlases. No standard MGI “HELLP mouse” should be asserted without model-specific curation.

Recent developments and evidence appraisal

The strongest 2023–2024 advances are: (1) expanding placental single-cell and multi-omic maps, with FLT1 and trophoblast/vascular cell states repeatedly implicated; (2) growing clinical adoption of PlGF and sFlt-1/PlGF testing for suspected preeclampsia, though not a substitute for HELLP criteria; and (3) improved recognition that postpartum nonresolving “HELLP” may instead be TTP or complement-mediated aHUS. The 2024 multi-omics review concludes that placental molecular findings are promising but inconsistent and require larger, standardized, subtype-specific validation. (ng2024biomarkersandpoint pages 1-2, cao2024placentaloriginsof pages 1-2)

The principal translational frontier is complement stratification. Human placental deposition, urinary biomarkers, functional assays, susceptibility variants, in-vitro inhibition, and animal rescue experiments collectively support complement as a biologically credible amplifier in a subset. They do not yet prove that all HELLP is complement-driven or that anti-C5 therapy improves outcomes. The three-participant eculizumab phase-1 experience is hypothesis-generating only. (burwick2022complementactivationand pages 1-7, NCT04103489 chunk 1, burwick2022complementactivationand pages 15-19)

Selected exact source statements

Burwick and Feinberg, published February 2022, state: “In women who develop preeclampsia and HELLP syndrome, there is a shift towards increased complement activation and decreased complement regulation.” DOI: https://doi.org/10.1016/j.ajog.2020.09.038. (burwick2022complementactivationand pages 1-7)
Cao, Saxena, and Gray, published 28 August 2024, state: “Transcriptomic studies in bulk placental tissue have identified many dysregulated genes in the PE placenta, including the PE signature gene, Fms-like tyrosine kinase 1 (FLT1).” DOI: https://doi.org/10.3390/ijms25179343. This is preeclampsia-spectrum evidence, not HELLP-specific validation. (cao2024placentaloriginsof pages 1-2)
Ng et al., published October 2024, state that newer diagnostic and imaging tests “are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care.” DOI: https://doi.org/10.1038/s43856-024-00642-4. (ng2024biomarkersandpoint pages 1-2)
Vera-Ponce et al., published 10 November 2025, report HELLP prevalence “0.39% (95% CI: 0.16%–0.72%),” while cautioning that it derives from only nine studies. DOI: https://doi.org/10.3389/frph.2025.1706009. (veraponce2025globalprevalenceof pages 1-2)

Knowledge-base cautions

Do not annotate CFH, CFI, CD46, CFHR1, CFHR3, HADHA, or HADHB as universally causal HELLP genes; evidence supports susceptibility, mechanistic overlap, or differential diagnosis.
Do not use sFlt-1/PlGF, complement biomarkers, NLR/PLR, MPV/PDW, proteomics, or transcriptomics as standalone diagnostic criteria.
Do not infer TTP or aHUS treatment from a HELLP label without reassessing postpartum trajectory, ADAMTS13, renal severity, and complement-mediated TMA.
Delivery remains the definitive placenta-directed treatment; eculizumab and high-dose maternal dexamethasone are investigational/controversial rather than established disease-modifying standards.
HELLP-specific PMID capture was incomplete in the retrieved corpus; DOI and ClinicalTrials.gov identifiers are therefore supplied where verified rather than inventing PMIDs.

References

(NCT07377786 chunk 1): Esraa Jaheen Ali. Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.. Sohag University. 2026. ClinicalTrials.gov Identifier: NCT07377786
(burwick2022complementactivationand pages 7-11): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.
(veraponce2025globalprevalenceof pages 1-2): Víctor Juan Vera-Ponce, Joan A. Loayza-Castro, Jhosmer Ballena-Caicedo, Lupita Ana Maria Valladolid-Sandoval, Fiorella E. Zuzunaga-Montoya, and Carmen Inés Gutierrez De Carrillo. Global prevalence of preeclampsia, eclampsia, and hellp syndrome: a systematic review and meta-analysis. Frontiers in Reproductive Health, Nov 2025. URL: https://doi.org/10.3389/frph.2025.1706009, doi:10.3389/frph.2025.1706009. This article has 73 citations.
(burwick2022complementactivationand pages 1-7): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.
(burwick2022complementactivationand pages 11-15): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.
(burwick2022complementactivationand pages 15-19): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.
(NCT04103489 chunk 1): The Use of Eculizumab in HELLP Syndrome. Johns Hopkins University. 2021. ClinicalTrials.gov Identifier: NCT04103489
(markin2024thromboticmicroangiopathyin pages 5-6): Л. Б. Маркін, К. Л. Шатилович, С. М. Сергійчук, Г. Я. Кунинець, and М. П. Лисий. Thrombotic microangiopathy in the postpartum period (literature review, clinical case report). Lviv clinical bulletin, pages 84-95, Sep 2024. URL: https://doi.org/10.25040/lkv2024.03.084, doi:10.25040/lkv2024.03.084. This article has 1 citations.
(ng2024biomarkersandpoint pages 1-2): Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, and Samuel B. Mabbott. Biomarkers and point of care screening approaches for the management of preeclampsia. Communications Medicine, Oct 2024. URL: https://doi.org/10.1038/s43856-024-00642-4, doi:10.1038/s43856-024-00642-4. This article has 53 citations and is from a peer-reviewed journal.
(NCT01138839 chunk 1): Dexamethasone Efficacy in HELLP I Syndrome. Universidad del Valle, Colombia. 2009. ClinicalTrials.gov Identifier: NCT01138839
(NCT07377786 chunk 2): Esraa Jaheen Ali. Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.. Sohag University. 2026. ClinicalTrials.gov Identifier: NCT07377786
(NCT06758960 chunk 1): Meryem Essafti. Analysis of Biological Progression and Regression of HELLP Syndrome in Time. CHU Mohammed VI Marrakech. 2023. ClinicalTrials.gov Identifier: NCT06758960
(cao2024placentaloriginsof pages 1-2): Chang Cao, Richa Saxena, and Kathryn J. Gray. Placental origins of preeclampsia: insights from multi-omic studies. International Journal of Molecular Sciences, 25:9343, Aug 2024. URL: https://doi.org/10.3390/ijms25179343, doi:10.3390/ijms25179343. This article has 36 citations.
(OpenTargets Search: HELLP syndrome): Open Targets Query (HELLP syndrome, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	5
Resolved	5
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	5
On topic	3
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Progression

Prevalence

Clinical Burden

Differential Diagnoses

Related Datasets

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

HELLP syndrome: disease-characteristics research report

1. Disease information

2. Etiology, risk, and protection

Causal framework

Risk factors

Protective factors and prevention

3. Phenotypes

4. Genetic and molecular information

No established causal gene

Susceptibility evidence

Epigenetics and chromosomal abnormalities

5. Environmental, lifestyle, and infectious information

6. Mechanism and pathophysiology

Causal chain and hierarchy

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Core laboratory diagnosis

Recommended work-up

Differential diagnosis

11. Outcome and prognosis

12. Treatment and real-world implementation

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Recent developments and evidence appraisal

Selected exact source statements

Knowledge-base cautions

Artifacts

Reference Validation